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of the thesis
Chapter I
Introduction & Outline
Introduction
Tuberculosis (TB) is and has been a major health problem in Africa. In low-income countries 
like most o f the countries in sub-Saharan Africa, the struggle against this disease is difficult and 
costly. W ith the introduction o f an effective strategy in 1964 introduced by W orld Health 
Organisation (W H O ) and the International U nion against Tuberculosis and Lung Disease 
(IUATLD) under the inspiration o f  D r K. Styblo, many o f the African countries were able to 
decrease the incidence o f tuberculosis.1-4 This strategy was based on the organisation o f a 
National Tuberculosis Programme (NTP), which was to be responsible for case finding and 
diagnosis, registration, monitoring, and treatment. Until the 1980s this strategy was successful. 
In the 1980’s the first cases o f  H IV  and its association with TB were reported. This co-infection 
resulted in a catastrophe. Tuberculosis resurged to the same level as in the fifties (figure 1). 
W H O  declared the epidemic a global emergency, an unprecedented step in the history o f this 
organization. Today, tuberculosis kills approximately 2 million people each year. More than 8 
million people, o f which 2 million in sub-Saharan Africa, will become ill w ith TB each year. The 
global epidemic is growing and becoming more dangerous. Someone in the world is newly 
infected with TB every second. Overall, one third o f the world’s population is currently infect­
ed with the TB bacillus. It is estimated that between 2002 and 2020, approximately 1000 mil­
lion people will be newly infected, over 150 million people will become ill, and 36 million will 
die o f TB - if  control is not further strengthened.
TB is a disease, which is spread through the air. Only people who are sick with pulmonary TB 
are contagious. W hen such people cough or sneeze they produce TB bacilli, Mycobacterium 
tuberculosis (M . tb), into the air. A person needs only to inhale a small num ber o f  these bacilli 
to be infected. Left untreated, each person with active, contagious TB will infect on average 
between 10 and 15 people every year. However, people infected with TB will not necessarily 
develop illness. The im m une system walls off the mycobacteria, which can remain dorm ant for 
years. W hen someone’s im m une system is weakened, the chances o f  becoming ill are greater. 
Since H IV  is capable to corrode the imm une system, and M . tb  tends to enhance the multipli­
cation o f HIV, H IV  and TB form a deadly combination, each accelerating the other’s progress. 
Someone who is infected with H IV  and at the same time with M . tb  is about 35 times more 
likely to become ill w ith TB than someone infected with TB who is not co-infected with HIV.
H IV  has a negative im pact on the treatm ent outcome o f  TB. For example in Malawi, the case 
fatality rate has increased for example from 6% in 1987 to 21% in 1995. In one report in 
Zom ba in the south o f Malawi, the case fatality rate was 18% in smear positive TB and 
40 — 50% in smear negative and extra-pulmonary tuberculosis.5 In Malawi, the first case of 
AIDS was reported in 1986. A study o f TB patients in 1986 found that 25-30%  were already 
infected with HIV. In 1995 this num ber had risen to 75%.
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Figure 1 N ew  notified TB cases in Malawi 1970-1995
Figure 2
Statistics (2001)
Total population 11 571 000
G D P  per capita (Intl $)* 500
Life expectancy at birth m /f  (years) 35.7 /36 .9
H ealthy  life expectancy at birth m /f  (years) 29 .0 /30 .7
A dult m ortality  m /f  (per 1000) 695 /636
Total health expenditure per capita (Intl $)* 38
Total health expenditure as % o f G D P 7.6
* International dollar: a com m on currency unit th a t takes
in to  account differences in the relative purchasing power of 
various currencies.
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The result is that TB is a leading cause o f death among people who are HIV-positive. It accounts 
for about 11% o f AIDS deaths worldwide. In sub-Saharan Africa, H IV  is the single most im por­
tant factor determining the increased incidence o f TB in the past 10 years.
Malawi
Situated in south-east Africa, Malawi is bordered by Tanzania on the north, by Zam bia on the 
west and by Mozambique on the south and east. Malawi is approximately 900 kilometres in 
length and ranges in w idth from 80 to 160 kilometres. The total area is about 118 500 km2, of 
which 94 000 km2 is land. The remaining area consists o f Lake Malawi. Malawi is divided into 
three main administrative areas, the N orthern, the Central and the Southern Regions. Every 
region is subdivided into districts, five in the N orthern, nine in the Central and eleven in the 
Southern region. W ithin each district there are administrative subdivisions known as Traditional 
Authorities, which are presided by chiefs. The smallest administrative unit is the village.
The climate is tropical continental with some maritime influences. Temperature and rainfall 
vary with altitude and proximity to the Lake. Malawi is a mainly agricultural country: 43%  of 
the population are farmers, while almost another 40%  does farming beside their official job. 
Malawi had its last population census in 1987. In 1987 the official population was almost 8 mil­
lion, whereas the population grows rapidly and recent estimates approximate 11.3 million. 
Rapid population growth has m eant increasing pressure on the GDP. This is clearly seen with 
regard to maize production: to achieve m inim um  food self-sufficiency for the nation there is a 
current annual shortfall o f maize production o f  about 900 000 tonnes.
There are nine main ethnic groups, a small but economically im portant Asian community and an 
even smaller European community. The main ethnic tribes in Malawi are the Chewa, Tumbuka 
and Yao tribes. Almost 50% o f the population is under the age o f 15 years. The official language 
spoken is English, whereas Chichewa is the second official language. The most important religions 
are Christianity (Protestants and Catholics) and Islam (the Yao tribe). There is a low literacy rate: 
56% in adults in 1995 with 72% in men and 42% in women. Secondary school enrolment is low 
with 22% o f males and 12% o f females gaining places at secondary school.
Politically, an im portant change was seen with the transition from a one-party system to a m ulti­
party democracy in 1994 and a new democratically elected government. The new Malawi 
Government com mitted itself to poverty alleviation as the central national policy objective. In 
terms o f  health, this new government adopted a policy with an objective o f  developing a sound 
health care system capable o f  preventing and curing disease. Due to the high infant, under five, 
and maternal m ortality (as a matter o f fact the highest in Africa, table 1), the health needs of 
mothers and children under five years o f  age have been given high priorities.
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Table  1 H ealth  Indicators in  M alawi
H ealth  Indicator Estim ated figures
C rude b irth  rate (births per 1000 population) 47
C rude death rate (deaths per 1000 population) 23
M aternal m ortality rate (per 100,000 live births) 620
U nder-5 m ortality  rate (per 1000 live births) 234
Infant m ortality rate (per 1000 live births) 135
Total fertility rate 6.7
Life expectancy at birth 39
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Service delivery should be improved by extending coverage, so that basic curative services for 
com mon diseases such as malaria, diarrhoea, and acute respiratory infections, would be widely 
available along with immunisations and family planning. Information, education, and com mu­
nication (IEC) programmes are claimed to be used to increase effective preventive behaviour.
Support o f  a new College o f Medicine within the University o f Malawi, is advocated to train a 
sustainable num ber o f doctors who are less vulnerable for brain drain and to create a more sci­
entific background for improvement o f  the health sector.
The results o f the new health policy up to the present day have been rather disappointing. Still, 
health parameters show bad or even worse statistics as compared to other countries in sub- 
Saharan Africa that appear to have similar conditions. Deteriorating economics, rapidly increas­
ing corruption, and poor working moral, are said to be causing this decline in standards. In 
addition, HIV/AIDS has had a devastating impact on the health systems. Possible causes o f this 
breakdown were an increased patient load, an increasing mortality o f the patients, and also of 
the health care workers themselves, and a reallocation o f funds towards expensive and not cost 
effective measures such as antiretroviral drugs for a limited section o f the population.
The National TB Control Programme
History o f Tuberculosis Control in Malawi
The first nam ed death from tuberculosis in Malawi was Shadrach Ngum uya in 1877 at Cape 
Maclear. From then until 1964, TB cases were diagnosed and treated according to available 
resources, but no actual TB control programme existed.
1964 to 1983  T he National Tuberculosis Control Programme in Malawi commenced in 1964 
when Malawi became independent. Assistance in the form o f equipment, transport and drugs was 
provided by the United States o f America through the University o f N orth Carolina. The pro­
gramme aimed at controlling tuberculosis (TB) through active case finding, treatment and pre­
vention. However, each district in Malawi worked independently in its efforts to control TB and 
so the programme lacked coordination. In 1969, a tuberculosis control unit and central registry
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was created at the Ministry o f Health Headquarters. The aims o f this unit were to coordinate 
activities in the districts and to provide on-going analysis o f TB cases in the country. The TB 
Control U nit was run by a newly appointed TB Control Officer and was further strengthened by 
the appointment o f Regional TB Officers to supervise and coordinate activities in the districts.
1984  to presen t tim e  In 1984, Malawi received assistance from the IUATLD. This organisa­
tion provided drugs for short course chemotherapy o f smear-positive TB cases and set in place 
a standardized reporting and evaluation system in all districts o f the country. The National TB 
Control Programme (NTP) was formed. Countrywide short course chemotherapy for the treat­
m ent o f sputum  positive cases was achieved in 1986. Technical assistance in the form o f two 
consultant visits each year was also established. In 1996, the D epartm ent for International 
Development (DFID), UK, provided assistance to the TB Control Programme in the form of 
technical assistance on the ground through a technical advisor, capital equipment, training and 
operational research. This supplemented the assistance from IUATLD. In 1999, the IUATLD 
formally ended its long term assistance to the Malawi NTP. In its place, donor assistance was 
provided by DFID, the Norwegian Agency for Development Cooperation (NORAD) and the 
Royal D utch Tuberculosis Association (KNCV). These three organizations have provided sup­
port to the N T P  up to the present time.
The problems of the NTP at present
Today, even though its 11.3 million people struggle daily with poverty, disease, and a terrible 
lack o f  resources, Malawi’s Tuberculosis Control Programme (NTP) is seen by many as a model 
for sub-Saharan Africa. Beside the structural approach advocated by the IUATLD, Malawi 
adopted the D O TS strategy advocated by W H O  in 1984 for smear positive cases o f pulmonary 
tuberculosis (PTB). DOTS (Directly Observed Treatment Short-course) consists o f five main 
pillars (see table 2)
T able  2  T h e  five p illars o f  D O T S
1 G overnm ent com m itm ent to a N T P
2 Priority to detect infectious disease cases by spu tum  smear microscopy
3 Standardised regimens o f short-course chem otherapy, given under direct observation for, at least, the 
intensive phase o f  treatm ent
4 Regular, un in te rrup ted  supply o f  drugs
5 M onito ring  system for program m e supervision and evaluation
This led to an increase in cure rates from 74%  in 1984 to 90% in 1987 and a short-lived opti­
mism about this new treatm ent strategy. AIDS struck the country in this very same episode. In
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1985 there were 5 334 new cases o f TB notified; by 1995 this num ber rose to 19 155 and cure 
rates declined to 63%. The N T P  as an organisation suffered under the increased burden. In 
addition, AIDS had a general devastating effect and resulted in a national breakdown in health 
services. The N T P  had to find innovative approaches to this disaster. In order to provide possi­
ble solutions an analysis o f constraints was made (table 3)
Table  3
Some constrain ts on  the  M alaw i N T P  in  1995
1 D iagnosis
— U p to 30%  o f smear positive patients in some districts diagnosed in the laboratory register were 
no t being registered and therefore no t placed on  treatm ent
— Long delays in the diagnosis o f smear positive T B  patients who were adm itted  to  hospital w ith risk 
o f nosocom ial transm ission to  health care workers
— Too m any smear-negative T B  patients related to spu tum  smears never being exam ined
— Possible delay in diagnosis because o f  consultation o f traditional healers
— D ifficult diagnosis o f  forms o f extra pulm onary  T B  such as T B  lym phadenitis, T B  meningitis
— Possible gender differences in access to health care
2 T reatm ent
— Congestion o f  patients in T B  wards who were receiving initial phase o f treatm ent
— Im proper directly observed treatm ent
— N o follow-up o f patients w ith  smear negative and extra-pulm onary TB
— H igh case fatality rate in H IV  related TB
— N o perspective for H IV  positive T B  patients besides treatm ent o f TB
— Possible high default rates in some districts
3 Laboratories
— Irregular supply o f slides
— Too little tim e spent exam ining smears
— Short-cuts (ie only one o f 3 spu tum  specimens from  each patient actually exam ined)
— Insufficient num bers o f laboratory staff
— Poorly m aintained equipm ent
— Viability o f smears questionable w ith long storage
4  Education
— Lack o f form al education sessions for patients
5 Supervision
— Lack o f regular supervision because o f no resources
6 Train ing
— N o regular train ing  seminars for different stakeholders such as health centre staff, traditional healers 
and village headm en
7  C om m unications and  docum entation
— Poor com m unication between all levels o f the N T P ; no com puters to assist in the collating, dissemi­
nating, and docum entation  o f  inform ation
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The N T P  tried to develop a strategy to be able to manage the new problems. A Programme 
M anagement Group (PMG) was formed with the Programme Manager (F Salaniponi), a scien­
tific TB Advisor (Prof. AD Harries, M D), the head o f  the D epartm ent o f Medicine o f the 
College o f Medicine (MJ Boeree, M D), the National TB Officer (T Nyirenda, M D) and a dis­
trict health officer w ith a special interest in TB and research (A Banerjee, M D). One o f the ideas 
o f  the PM G was to organise a specific research programme in collaboration with W H O  and 
D FID . Several research proposals, based on the constraint analysis, were developed and 
launched. This resulted in a research agenda (table 4).
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The research based on this analysis, was to be conducted in order to better define -with data- 
the problems o f TB control in Malawi and to test interventions to solve those problems. The 
results o f this research had to contribute to a continuous adjustment o f policy and practice, and 
therefore, be able to influence and improve the care o f TB patients. Two examples o f this phi­
losophy are demonstrated in the research on the role o f traditional healers (chapters IV and V) 
and the research to the efficacy on survival and occurrence o f  disease o f cotrimoxazole (CTX) 
prophylaxis in H IV  seropositive PTB patients. Firstly, the finding that more than one third of 
sputum  smear-positive PTB patients had visited a traditional healer before seeking regular med­
ical care with a median delay o f 4 weeks, led to the implementation o f  a new policy towards tra­
ditional healers. In a series o f  meetings in 1997 to 2001 with traditional healers and other influ­
ential members o f the community, information was collected from thousands o f traditional 
healers, education was given about TB and the NTP, and referral slips were distributed to send 
TB suspects for sputum  examination. Funds were obtained to continue these com munity edu­
cation sessions.
Secondly, on the basis o f  the findings o f the study on CTX  prophylaxis and other studies in the 
country, a meeting was held in October 2002. The outcome o f  this meeting was a policy state­
m ent which a) endorsed that Voluntary Counselling and Testing for H IV  (VCT) and CTX 
prophylaxis for H IV  seropositive TB patients be continued in those districts where it has been 
started, b) encouraged V C T plus CTX  prophylaxis for H IV  seropositive TB patients to be 
expanded into other districts in a phased approach with results carefully m onitored by the N T P 
c) urged that the N T P  encourage and work with its partners to conduct a randomised con­
trolled trial to determine the efficacy o f  C TX  prophylaxis with and w ithout antiretroviral 
therapy in H IV  seropositive TB patients and d) requested all parties to keep up to date with any 
new information about the efficacy o f CTX  prophylaxis in the region and act accordingly if 
evidence suggests that CTX  has harmful consequences.
T his in troduction  is largely based on a docum ent published by the P M G , under auspices o f the W H O , the NTP, the 
IU A TLD  and D F ID .1
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Table  4  T B  Research A genda
CASE D E T E C T IO N
1 D ifficulties faced by  T B  suspects using  p resen t case de tection  system
Role o f  traditional healer in case detection *
Gender determination*
2 Inefficiencies w ith in  the  passive case find ing  system
H ealth  centre and ou t-patien t perform ance in dealing w ith cough and T B  suspects 
Delays between spu tum  submission and smear exam ination 
Sputum  storage a nd  smear/culture viability
Reasons fo r  diagnostic delay ^
3 L aboratory  perform ance 1 7
Knowledge and practice o f recom m ended laboratory procedures 
Im provem ent o f smear sensitivity 
Assessment o f safety procedures
4  D iagnosis o f  P u lm onary  TB
Assessing different strategies for screening T B  suspects 
% o f  smear positive patients who do no t get registered or treated
% o f  smear-negative PT B  patients w ith no smears done, w ith false positive smears, w ith  another 
diagnosis and w ith genuine T B  
Accuracy o f chest radiograph diagnosis 
Improvement o f  strategies in diagnosis o f  form s o f  E P TB
5 Paediatric  T B
Im proved diagnosis
6 H ig h  risk  groups
Prevalence o f  T B  in  prisoners 
Prevalence o f  T B  in  health care workers 
Prevalence o f  T B  in secondary school children
CASE H O L D IN G  A N D  T R E A T M E N T
1 T rea tm en t delivery
Decentralised care in urban end rural environm ents 
Use o f a unified regimen for all types o f  TB 
Integration o f T B /H IV /S T D  care
2  A dherence  to  tre a tm en t
Assessment o f  true extent o f  defaulters 
Reasons fo r  defaulting behaviour 
Interventions to reduce transfer ou t rates
3 R eactions to  tre a tm en t
M onitoring  adverse reactions on systematic basis
4  Sm ear-negative p u lm o n a ry  T B  a n d  e x trap u lm o n a ry  TB
Assessment o f  treatm ent outcom e through  routine N T P  
Assessment o f  treatment outcome in a research setting*
Assessment o f  treatment outcome in relation to H I V  an d  other clinical parameters
5 M orta lity
Treatm ent outcom es in smear-negative PTB and EPTB , especially in relation to H IV  status 
Interventions to reduce mortality in HIV-positive T B  patients e.g. cotrimoxazole prophylaxis*
6  M o n ito rin g  o f  tre a tm e n t
Use o f simple measures to m onito r patien t compliance in the continuation  phase o f treatm ent
7  D ru g  security
M ethods to  ensure drug  security at all levels
* topics, which led to studies in this thesis, are indicated in italic
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Outline of the thesis
This thesis consists o f six studies that were performed in relation to the research agenda m en­
tioned above, in collaboration with the Departm ent o f Medicine and the N TP 
We hypothesized that gender was a factor in the access to the health care systems in relation to 
case finding. This question was addressed in a study described in Chapter II. In the last 10 years 
in Malawi male notifications have consistently outnumbered female notifications. This hypothe­
sis that women are under notified was tested by an operational research study o f gender differ­
ences in numbers o f TB suspects submitting sputum  specimens and numbers o f suspects with 
positive sputum  smears.
There are several procedures to diagnose TB lymphadenitis. We asked the question which is the 
best locally applicable strategy for the diagnosis o f TB lymphadenitis; our investigations are 
described in Chapter III. In a prospective study the results o f basic procedures for the diagno­
sis o f  tuberculous lymphadenitis are compared with the outcome o f histology and/or culture.
In Chapter IV we addressed the question whether traditional healers were responsible for a 
possible diagnostic delay. Their role and their opinion are analysed in a questionnaire study 
involving both patients and traditional healers.
In Chapter V  we tried to answer the question which aspects o f care seeking behaviour and diag­
nostic processes in smear positive PTB patients are relevant. Amongst the aspects looked at were 
time o f diagnosis, the health institution that was visited, the num ber o f visits made, and the 
effect o f  antibiotics.
In Chapter VI, the question o f viability o f mycobacteria was addressed in a study to see how 
long sputum  samples can be stored at room temperature or in the refrigerator w ithout losing 
the ability to demonstrate acid fast bacilli in a Ziehl Neelsen stain or to remain positive when a 
culture for mycobacteria is done. This issue has practical implications for the diagnostic process 
o f  smear positive TB in situations o f time delay and frequent power cuts.
A major question within the context o f his thesis was whether we could accomplish an increased 
survival in H IV  co-infected PTB through prophylaxis with cotrimoxazole with a single dose of 
480 mg as compared to the double dosage o f 480 mg, a historical control group, and the 
national case fatality rate (Chapters VII and VIII).
In Chapter IX, the problem o f treatm ent compliance w ithin the N T P  is addressed. We were 
interested in the reasons for default o f TB treatm ent and present status o f smear positive PTB 
patients who were registered to have defaulted treatment.
Finally, a critical review o f TB control in the face o f the H IV  epidemic concludes this thesis in 
Chapter X. This paper was published in first 1998 and an addendum is given in Chapter Xa 
updating it with newer developments in the era o f antiretroviral treatment.
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Gender
Summary
Objective: To examine gender differences in sputum  submission and sputum  smear positivity. 
M ethods: Laboratory registers in all diagnostic units in 8 districts in Malawi were examined for 
the years 1995 and 1996.
Results: During a 12-month period (averaged between 1995 and 1996), 26 624 new TB sus­
pects submitted sputum  samples o f whom 3282 (12.3%) were smear-positive. Significantly 
more males submitted sputum  (52%) compared with females (48%), and significantly more 
males (53%) were smear-positive compared with females (47%, p < 0.05). Rates o f sputum  sub­
mission per 100 000 adults were also significantly higher for males (1203) than females (1032). 
C onclusion: In Malawi, fewer females are submitting sputum  samples and are being diagnosed 
with smear-positive TB compared with males.
Introduction
Gender is recognised as an im portant variable in infectious disease epidemiology. A 1998 
review1 on gender differences in tuberculosis (TB) suggested that women in low-income coun­
tries were probably under notified. However, the data analysis in that review was based on 
studies going back 30 years previously. Despite the upsurge o f HIV-related TB in sub-Saharan 
Africa, there has been little recently published data on the relationship between gender and TB 
case notifications.
In the last 10 years in Malawi, male TB notifications have consistently outnum bered female 
notifications (Malawi National Tuberculosis Programme [NTP]). We were interested in whether 
there were any gender differences in 1) the num ber o f  TB suspects submitting sputum  speci­
mens for examination o f acid-fast bacilli (AFB), and 2) the num ber o f suspects with positive 
sputum  smears. We carried out an operational research study to investigate this further.
Methods
Laboratory sputum registers
Every laboratory in Malawi that performs sputum  smear microscopy for AFB records results in 
a sputum  register. For each patient submitting sputum, a unique num ber is given and a record 
made o f the name, address, age, sex, place o f submission, category (i.e., new suspect or follow- 
up patient), num ber o f specimens received and the sputum  smear results. Sputum examination 
is a free service.
C H A P T E R  II
Data collection
Eight out o f 25 districts were chosen to provide appropriate geographic representation from the 
north to the south o f  Malawi. W ithin each district, all laboratories performing sputum  smear 
microscopy in government/ mission hospitals or health centres were visited. There were 27 
laboratories in nine government hospitals, ten mission hospitals and eight health centres. In 
each laboratory, the laboratory sputum  registers were reviewed. The following information was 
obtained for each o f the years 1995 and 1996: total num ber o f new TB suspects submitting spu­
tum  specimens, place o f  submission, num ber o f male and female suspects, and num ber o f male 
and female suspects w ith positive sputum  smears. From 16 hospitals, 100 males and 100 females 
consecutively listed in the laboratory register from 1 January in 1995 and 1996 were identified, 
and ages (if recorded) were obtained.
Population distribution
The population o f Malawi and the eight districts was obtained for the year 1996 from popula­
tion estimates based at the national statistics department. Population numbers were obtained in 
relation to age and sex.
Calculations and analysis
D ata for the two years 1995 and 1996 were combined. The numbers o f males and females sub­
m itting sputum  samples and the numbers who were smear-positive were calculated for a 12- 
m onth period. Annual rates o f sputum  submission and smear-positivity were calculated per 
100 000 persons aged 15 years or more using population estimates for 1996. Epi-Info version 
6.0 was used for data collection. For gender comparisons, X2 tests, odds ratios (OR), 95% 
confidence intervals (CI) and p values were calculated, differences at the 5% level being 
regarded as significant.
Results
In 1996, the estimated population o f Malawi aged 15 years or more was 5 735 730 with 47% 
males and 53% females. In the eight districts, there were 2 389 852 persons aged 15 years or 
more, w ith 48% males and 52% females.
In laboratory sputum  registers, age was no t recorded for 18% o f males and females respective­
ly. O f  2622 males and 2613 females for whom age was recorded, the age distribution is shown 
in the Figure; 2% o f males and 3% o f females were aged under 15 years. A significantly higher
Gender
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proportion o f females (61%) were aged 15 - 34 years compared with males (45%, p < 0.05). 
During a 12-month period (averaged between 1995 and 1996), 26 614 new TB suspects sub­
m itted sputum; o f  these, 3282 (12.3%) were smear-positive. Significantly more males submit­
ted sputum  and were smear-positive compared with females (Table). This significant difference 
was found at government and mission hospitals, although in the health centres no significant 
differences were found.
T able  1 N u m b er o f  males and  females su bm itting  sp u tu m  and  w ho w ere sp u tu m  sm ear-positive during  
a 12-m onth  period  according to  type o f  in s titu tion .
M ales Females O R  [95%  CI]*
n(%) n(%) n(%)
N um ber subm itting  sputum 13 784 (52%) 12 831 (48%) 1.15 [1.12-1.19]#
A t governm ent hospital 7 651 (51%) 7 305 (49%) 1.1 [1.05 -1.15]#
A t mission hospital 4 862 (54%) 4 224 (46%) 1.32 [1.25 -1.41]#
A t health centre 1 271 (49%) 1 302 (51%) 0.95 [0.85 -1.06]
N um ber spu tum  smear positive 1 751 (53%) 1 531 (47%) 1.31 [1.19 -1.44]#
A t governm ent hospital 962 (53% ) 861 (47%) 1.25 [1.09 -1.42]#
A t mission hospital 638 (54% ) 534 (46%) 1.43 [1.21 -1.69]#
A t health centre 151 (53%) 136 (47%) 1.23 [0.88 -1.73]
% of fiusp^as su&milling sputum 
4 0 1---------------------------------------------------
Ays (years)
Odds ratios (OR) with 95% confidence intervals (95%CI) are shown for comparisons between males and females 
# p < 0.05 - significant differences between males and females
C H A P T E R  II
Annual rates o f sputum  submission and sputum  smear positivity per 100 000 adults aged 15 
years and above in the eight districts were respectively 1114 and 137 . Rates o f sputum  sub­
mission per 100 000 adults were 1203 for males and 1032 for females (O R = 1.17, 95% CI 
1.14 - 1.20). Rates o f smear-positive sputum  per 100 000 adults were 153 for males and 123 
for females (O R  = 1.24, 95% CI 0.97 - 1.59).
Discussion
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This study shows that in 1995 to 1996 in eight districts in Malawi, more males than females 
1) submitted sputum  specimens for AFB examination and 2) were found to be sputum  smear- 
positive. These differences were found at both government and mission hospitals. Similar dif­
ferences were obtained when results were analysed in relation to rates per 100 000 adults per 
year.
This study conducted w ithin the operational framework o f  the Malawi N T P  has some limita­
tions. D ata validity depends on accuracy o f  records in laboratory sputum  registers and accura­
cy o f sputum  smear microscopy, and mistakes may be made under routine conditions (personal 
observations). We also did not obtain inform ation on the relationship between gender, number 
o f patients presenting to health facilities with a cough and the num ber submitting sputum  for 
AFB examination. A study at one referral site (Queen Elizabeth Central Hospital, Blantyre),2 
showed that 18% o f out-patients complained o f  cough. O f  those with cough, 31% had a cough 
> 3 weeks and nearly 60% were referred for sputum  examination. N o gender differences were 
noted, although this study cannot be said to be representative o f  the country. However, we 
believe that the results o f the present study (although some pieces o f inform ation are missing) 
are probably representative o f the country. The population in the eight districts constituted just 
over 40% o f Malawi’s population, the gender distribution reflected that seen in the country, the 
three regions which serve the main ethnic groups were covered, and large numbers o f patients 
were included. We feel justified in calculating our sputum  submission and sputum  smear-posi­
tive rates per 100 000 for persons aged 15 years and over because age-related data showed that 
less than 4% o f males and females submitting sputum  were aged 14 years or below.
It was not unexpected that many more young women aged 15 - 24 years submitting sputum 
compared with men. H IV  infection rates in Malawi are much higher in women aged 15 - 24 
years compared with men o f the same age (National AIDS Control Programme), and H IV  
infection is strongly associated with the development o f TB.3>4
This study suggests that gender differences are im portant in the epidemiology o f  TB in Malawi.
The N T P  needs to obtain more data on male and female patients about the process from onset 
o f cough to sputum  submission, diagnosis, registration, treatment and final treatm ent outcome.
Gender
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Summary
The human immunodeficiency virus (HIV) epidemic is associated with a marked increase of 
tuberculosis cases. The influence o f H IV  on diagnostic methods for tuberculous lymphadenitis is 
less clear. In an environment o f high H IV  and tuberculosis prevalence in Blantyre, Malawi, a 
prospective study compared results o f basic procedures diagnosing tuberculous lymphadenitis with 
the outcome o f histology and/or culture. One hundred out-patients, aged 15-55 years, with extra­
inguinal lymphadenopathy not responding to general antibiotics, entered the study. Among 52 
cases, with whom all procedures were carried out in accordance with the protocol, 38 (73%) were 
diagnosed as tuberculous lymphadenitis; 84% of the latter (32/38) were seropositive for HIV. 
Needle aspirate and biopsy smears stained by the Ziehl-Neelsen technique contributed little to 
detecting tuberculosis, 8% and 11% respectively. In contrast, macroscopic caseation o f excised 
lymph nodes showed a high yield o f 82%, which was similar to histology, and higher than that o f 
Lowenstein-Jensen culture (61%). The study suggested that H IV  positivity o f tuberculous lym­
phadenitis patients decreased the possibility o f histology and culture both being indicative of 
tuberculosis (odds ratio 0.10; p=0.06). Consequently histology results, often used as the single 
definitive method, failed to diagnose 18% (7/38) o f tuberculosis cases. However, it was reassuring 
that 4 simple methods, which can safely be carried out at district level, could be expected to diag­
nose 80-95% o f tuberculous lymphadenitis cases in a timely and cost-effective manner.
Introduction
Malawi has high human immunodeficiency virus (HIV) infection rates. In 1993, 32% of 
mothers visiting the antenatal clinic in an urban area, and 12% in rural areas, were seropositive 
for H IV 1 The H IV  epidemic is associated with a marked increase in the number o f cases o f tuber­
culosis in general,2 and extrapulmonary cases in particular.3-5 In Malawi, the number o f tubercu­
losis cases has increased threefold from 6301 to 19 195 over the last 10 years (1986-1995). In the 
same period, the Queen Elizabeth Central Hospital in Blantyre registered 4 times as many tuber­
culosis cases in total, and extra-pulmonary tuberculosis increased twelvefold to 893 in 1995.6 The 
greater increase at the hospital reflects the higher H IV  infection rates in urban Malawi.7 
The influence o f H IV  infection on diagnostic methods for tuberculous lymphadenitis is uncer­
tain, despite clear descriptions o f the non-reactive histopathology related to H IV  infection.8 To 
develop recommendations for a protocol that takes into account limited laboratory facilities and 
availability o f personnel at the district level, a prospective study was conducted to compare basic 
diagnostic procedures for tuberculous lymphadenitis with the results o f  histology and/or cul­
ture. The influence o f  H IV  infection on these findings was assessed. The study took place in a 
routine out-patient departm ent setting. Except for H IV  testing, no additional resource was 
made available or used to carry out the research.
C H A P T E R  III
Methods
Selection o f patients
One hundred out-patients aged 15-55 years attending the Queen Elizabeth Central Hospital in 
Blantyre, Malawi, were selected during the period April 1994 to April 1995. Patients who pre­
sented with lymphadenopathy in one or more extra-inguinal sites were issued with general 
antibiotics for 7-10 d and reviewed after a week. Patients who did not improve on treatment 
were included in the study. After pre-counselling and consent, blood for H IV  testing was taken, 
and an appointm ent was made for needle aspiration and lymph node excision.
Procedures
Under local anaesthesia, wide needle aspiration o f an enlarged lymph node was performed with 
a 19-gauge needle.10 The aspirate was spread on slides and dried in air. The same lymph node 
was then removed, cut in half, and macroscopically examined for caseation. Fluid from the cut 
surface o f  the lymph node was spread on slides and air-dried. Slides were stained by the Ziehl- 
Neelsen (ZN) m ethod and examined for acid-fast bacilli. H alf o f  the lymph node was fixed in 
formalin and sent for histological examination. The other half was used to inoculate 
Lowenstein-Jensen (LJ) cultures. Blood sera were tested for HIV-I and HIV-2 antibodies with 
Biochem DetectTM enzyme-linked im m unosorbent assays (ELSA) and SerodiaTM H IV  particle 
agglutination tests.
Definition o f tuberculosis lymphadenitis and H IV  status
The diagnosis o f tuberculous lymphadenitis was established when LJ culture yielded mycobac­
teria and/or a histology result showed granulomatous and caseating lymphadenitis consistent 
with tuberculosis (this was the definitive standard technique). Non-tuberculous lymphadenitis 
was diagnosed when both histology and culture results were inconsistent with tuberculosis. 
H IV  serostatus was recorded as positive if both the ELISA and particle agglutination test were 
positive, and negative if both tests were negative. Discordant test results were recorded as inde­
terminate.
Statistical analysis was done with the aid o f EpiInfo, version 6-02. Confidence intervals were 
calculated at the 95% level. W hen cell values were 5 or below, Fisher’s exact 2-tailed values o f  p 
and analogous exact confidence intervals were calculated. Sensitivity, specificity, and positive 
and negative predictive values were calculated with standard formulae.
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Results
From 100 patients enrolled, the following records were available: 83 wide needle aspiration Z N  
smears; 80 records on macroscopic caseation o f excised lymphnodes; 83 biopsy Z N  smears; 85 
histology reports; 68 LJ cultures; 99 H IV  serology results. Incomplete results were related to 
unrecorded observations, lost specimens, sending incorrect specimens, and the fact that 10 
patients failed, for unknown reasons, to report for their surgical procedures. All procedures were 
carried out in accordance with the protocol for 52 cases; the following analysis focuses on the 
52 complete sets o f  results.
Thirty-eight o f these 52 patients (73%) were diagnosed as tuberculous lymphadenitis, and 32 
o f  the 38 (84%) were H IV  seropositive. Non-tuberculous lymphadenitis patients had slightly 
lower H IV  seropositivity (11/14; 79%). The H IV  status o f the 48 patients excluded from fur­
ther analysis was similar; 85% (40/47) were H IV  seropositive. No discordance was observed 
between the 2 tests for H IV  infection.
Acid-fast bacil1i were detected in 3 wide needle aspirates and 4 biopsy smears, and all were con­
firmed by histology or culture, giving a positive predictive value o f  100%. In all these cases, 
macroscopic caseation o f the excised lymph node was observed (Table 1).
T able  1 Sensitivity, specificity an d  predictive values o r d iagnostic  procedures fo r tuberculous lym ­
phaden itis  com pared to  h isto logy a n d /o r culture
Predictive value
Sensitivity Specificity Positive Negative
W ide needle aspiration
D irect smear 8%  (3/38) 100% (14/14) 100% (3/3) 29% (14/49)
Biopsy
Caseation 82% (31/38) 71% (10/14) 89% (31/35) 59% (10/17)
D irect smear 11% (4/38) 100% (14/14) 100% (4/4) 29% (14/48)
Histology 82% (31/38) 100% (14/14) 100% (31/31) 67% (14/21)
Culture 61% (23/38) 100% (14/14) 100% (23/23) 48% (14/29)
C om bina tiona 82% (31/38) 71% (10/14) 89% (31/35) 59% (10/17)
a Wide needle aspiration direct smear+biopsy caseation+biopsy direct smear.
Macroscopical caseation was observed in 35 cases and tuberculosis was confirmed in 31 o f them, 
giving a positive predictive value o f 89%.
All the isolates grown in LJ culture were identified as Mycobacterium tuberculosis, based on the 
time taken for growth, colony morphology, and Z N  staining.
C H A P T E R  III
Yield o f diagnostic procedures
Histology, caseation and culture detected a high proportion o f cases (Table 2). The contribution 
o f wide needle aspiration and biopsy smears was low.
Table  2  Yield o f  d iagnostic procedures fo r tuberculous lym phadenitis
Tuberculosis patients 
All H IV  positive H IV  negative
N o .o f patients 38 32 6
W ide needle aspiration
D irect smear 3 (8%) 3 (9%) 0
Biopsy
Caseation 31 (82%) 26 (81%) 5 (83%)
D irect smear 4 (11%) 4 (13%) 0
Histology 31 (82% ) 25 (78%) 6(100% )
Culture 23 (61%) 18 (56%) 5 (83%)
C om bination3 31 (82%) 26 (81%) 5 (83%)
b Wide needle aspiration direct smear+biopsy caseation+biopsy direct smear.
Diagnostic yield related to H IV  status
All confirmed tuberculosis patients with acid-fast bacilli found in aspirates and biopsy smears 
were seropositive for HIV. All 6 H IV  seronegative tuberculosis patients were histologically diag­
nosed as tuberculous lymphadenitis. Only 25 o f the 32 H IV  seropositive patients were diag­
nosed by histology (Table 2). N o statistically significant association was found between the 
results o f aspiration, biopsy smears or histology and H IV  status.
Results o f histology and culture were both indicative o f tuberculous lymphadenitis in 16 o f  38 
cases; 5 o f the 16 were H IV  seronegative and 11 were seropositive. W ith the remaining 22 cases, 
only one o f the 2 procedures gave a positive result for tuberculosis, 7 by culture and 15 by his­
tology. One patient w ith a histology result consistent w ith tuberculous lymphadenitis (but a 
negative culture) was seronegative for HIV; all the other 21 cases were H IV  positive. The H IV  
status o f the tuberculous lymphadenitis patients suggests a negative influence o f H IV  infection 
on the possibility o f both histology and culture being indicative o f tuberculosis (odds ratio 
[OR]=0.10; exact confidence limits zero-1.17; Fisher’s exact 2-tailed p=0.06).
Histology and culture: sensitivity and negative predictive values
The results o f  histology and culture on their own were compared with the combined outcome 
o f both tests to estimate sensitivity and negative predictive values (Table 1).
Histology was indicative o f tuberculosis in 31 o f 38 diagnosed cases o f tuberculous lym­
phadenitis, giving a sensitivity o f 82%. Growth o f M. tuberculosis occurred with 7 o f  21 histo-
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logically non-tuberculosis cases. Histological examination therefore had a negative predictive 
value o f  67% (14/21).
Cultures gave positive results for tuberculosis in 23 o f the cases, a sensitivity o f 61%. Histology 
was positive for tuberculosis in 15 o f the 29 patients with negative cultures, a negative predic­
tive value o f 48%  (14/29) for culture.
Discussion
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Yield o f diagnostic procedures
W ide needle aspirations and biopsy smears made only small contributions to the diagnosis o f 
tuberculous lymphadenitis (8% and 11%, respectively). Others have reported higher sensitivi­
ties, varying from 28% 9 to 35% for aspiration and 53% for biopsy smears.10 There are 3 possi­
ble reasons for the higher field in other reports. Firstly, other studies included in-patients,9,10 
who present in a later stage o f H IV  infection and tuberculosis11 w ith a more highly compro­
mised imm une system; more acid-fast bacilli cells can be detected in their lymph nodes. 
Secondly, other studies included patients for whom  only smears were examined to confirm 
tuberculous lymphadenitis,10 thus increasing the num ber o f positive results. Thirdly, our study 
excluded sputum  positive patients since further investigations would not have resulted in dif­
ferent treatm ent o f the patient.10 A study o f out-patients in rural Zam bia12 also reported rela­
tively low yields from smear results, 12% for aspirates and 15% for biopsies.
In contrast to the low yield o f  aspirate and biopsy smears, macroscopic caseation o f excised 
lymph nodes gave a high yield in our out-patient departm ent setting, similar to that o f 
histology (82%) and higher than LJ culture (61%). The overall positive predictive value of 
diagnosing tuberculosis by macroscopic caseation was 89%, but it improved during the second 
part o f the study (patients no. 51-100) to give a positive predictive value o f 100% (15/15). The 
improvement could have been due to experience gained, and to the fact that only one surgeon 
carried out the procedures, instead o f 4.This is an encouraging result, but it reminds us o f the 
need for proper supervision and guidance when new protocols are introduced.
Following Perenboom et al.,10 using a ‘step- wise’ addition o f the 3 diagnostic methods, a cum u­
lative total o f 31 o f the 38 proven tuberculous lymphadenitis patients was detected retrospec­
tively: firstly, (i) Z N  staining o f wide needle aspirates diagnosed 3 patients; (ii) macroscopic 
caseation found 28 more; (iii) biopsy smears did not detect any case o f  tuberculosis that had not 
been found by the previous 2  methods.
The contribution o f aspiration m ight be improved by adding an observation described:9 in 
41%  o f the cases with macroscopic caseation, caseation was also seen in the wide needle aspi­
rate, with a positive predictive value o f 100% for tuberculous lymphadenitis. This aspect was 
not covered in our study, although the surgeons sometimes spontaneously reported (but did not 
record) macroscopic caseation o f the aspirate.
C H A P T E R  III
Negative predictive value o f histology
In many sub-Saharan African countries, results o f histological examination are often used as the 
standard. O ur study revealed a negative predictive value o f  67%, implying that tuberculosis was 
not identified in 33% o f patients with negative histology results. If  histology had been the only 
available diagnostic procedure, 18% o f the tuberculosis cases would not have been detected and 
treated. This raises concerns about the effectiveness o f histology as a single tool w ith which to 
diagnose tuberculous lymphadenitis.
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Does H IV  infection influence results o f diagnostic procedures?
There is no dispute that the H IV  epidemic bas contributed to changing patterns o f tuberculo­
sis infection. More contentious is the effect o f H IV  infection on diagnostic m ethods.13-17 
Although hyporeactive or anergic responses, w ith numerous bacilli in the lymph nodes o f tuber­
culous lymphadenitis patients infected with HIV, have been described clearly,9 the influence of 
H IV  on the yield o f diagnostic methods for tuberculous lymphadenitis is less certain. Neither 
Bem et al.9 nor Perenboom et al.10 detected any difference in diagnostic yield related to H IV  
status. O ur study suggested that H IV  seropositivity o f tuberculous lymphadenitis patients 
decreased the possibility o f histology and culture both being indicative o f tuberculosis 
(OR=0.10, p=0.06). In addition, the results tentatively suggested that histology is a more sen­
sitive tool to diagnose tuberculosis in H IV  seronegative patients, all o f whom were diagnosed 
by histology, compared with only 78% o f those who were H IV  seropositive. However, due to 
the low numbers in general, and especially o f  H IV  seronegative patients, no significant associa­
tion was found (OR=0; exact confidence limits zero-3.92; Fisher’s exact 2-tailed p=0’57). O ur 
finding that H IV  infection might decrease the sensitivity o f diagnostic procedures for tubercu­
lous lymphadenitis needs further investigation.
Recommendations
Records for only 52 o f  100 enrolled outpatients could be used in the analysis. Perenboom et 
al.10 were able to acquire complete data for 53% (68/128) o f their in-patients. These low return 
rates reflect the difficulties o f research in routine settings outside a research environment. A pro­
tocol for diagnosing tuberculous lymphadenitis should therefore be simple and pro-active, 
reducing the chance o f a missed diagnosis due to difficulties in protocol procedures. Therefore, 
we suggest primarily the use o f 4 simple methods to diagnose tuberculous lymphadenitis as 
shown in the Figure.
These 4 methods have achieved 100% positive predictive values for diagnosing tuberculous 
lymphadenitis in earlier studies,10’11 and can easily and safely be carried out at district level. If 
any o f these tests is positive, the diagnosis o f tuberculous lymphadenitis can be made and there
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Figure 1 Protocol for diagnosis o f tuberculous lymphadenitis using 4 simple techniques 
(developed from the flow chart o f Perenboom;10 AFB=acid-fast bacilli.
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is no need to make further investigations, thus saving both cost and time. The recording of 
caseation o f the wide needle aspirate should increase the usefulness ofw ide needle aspiration in 
an out-patient department setting. We expect that 80-95% o f tuberculous lymphadenitis cases 
can be diagnosed by these methods in a timely and cost-effective manner in areas with high 
prevalences o f tuberculosis and H IV  infection.
Conclusions
The contribution o f aspirate and biopsy smears in diagnosing tuberculous lymphadenitis in out­
patients was low. In contrast, examination for macroscopic caseation o f the cut surface o f lymph 
nodes had high sensitivity. O ur study raised concern that sophisticated procedures such as his­
tology and culture, which are developed to diagnose tuberculosis, fail to do so, especially with 
HIV-associated tuberculous lymphadenitis. Histology missed 18%  o f the tuberculosis cases, all 
o f  whom were seropositive for HIV.
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C H A P T E R  II I
There is a need to develop simple, pro-active methods to diagnose tuberculous lymphadenitis 
in out-patient departments. Four simple methods, which can easily and safely be carried out at 
district level, should diagnose 80-95% o f tuberculous lymphadenitis cases in a timely and cost- 
effective manner.
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Summary
Setting: Queen Elizabeth Central Hospital (Q EC H) and Blantyre district, Malawi.
Objective: To investigate the use that tuberculosis (TB) patients in Malawi make o f traditional 
healers and traditional medicine.
Design: A questionnaire study was carried out on 89 smear-positive pulmonary TB patients 
adm itted to Q EC H . Seven traditional healers in Blantyre were also interviewed about their 
knowledge, attitudes and practice o f patients whom  they considered to have TB.
Results: O f the 89 patients, 33 (37%) visited a traditional healer before seeking regular 
medical care. Patients spent a median length o f 4 weeks with the traditional healer. During this 
time, 24 patients did not improve or deteriorated while on traditional treatment. N o patient 
was referred to the medical services by the traditional healer. All traditional healers claimed to 
know about TB. Four said they would refer a patient to hospital if  their treatm ent was not cura­
tive. In 1995, six traditional healers claimed to have cured 116 patients with TB.
C onclusion: It is im portant to involve traditional healers in the educational activities o f the 
National TB Control Programme. These healers need to be taught to recognise and refer 
patients with TB, whom they should not treat, but at the same time be encouraged to admin­
ister safe treatments for conditions which are more amenable to their practice.
Introduction
TUBERCULOSIS (TB) is a major cause o f m orbidity and m ortality world-wide, with 95% of 
new cases in 1990 occurring in developing countries.1 In the W orld Health Organization 
(W H O )’s African Region the incidence o f TB in 1990 was 1.4 million cases, the majority of 
which occurred in sub-Saharan Africa.2 Eighty percent o f cases involve persons in their pro­
ductive years o f  life (15-59 years), and it has been estimated that 26%  o f avoidable adult deaths 
are due to T B .2
The hum an immunodeficiency virus (HIV) infection in sub-Saharan Africa is now strongly 
associated with TB. In Malawi, in 1989 52% o f TB patients were HIV-seropositive3 and in 
1993-1994 in a central hospital in Blantyre 75% were HIV-seropositive.4 As a consequence of 
this strong association between the two infections there has been a big upsurge o f TB in many 
African countries, including Malawi, in the last 10-15 years.
Case detection in most sub-Saharan African countries depends on passive case finding. Health 
workers are taught to suspect pulmonary tuberculosis (PTB) if a patient has a persistent cough 
for more than three weeks, particularly if there is associated weight loss, fever, chest pain or 
haemoptysis.5 Such patients should be referred to the health services for confirmation o f the 
diagnosis, primarily by sputum  microscopy examination. In theory, passive case finding o f  PTB 
cases should be successful because 90% o f smear-positive PTB cases develop a productive cough
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soon after the onset o f the disease, and this should persuade the patient to seek medical advice.2 
However, under routine conditions, only about a third to a half o f smear-positive TB cases are 
routinely diagnosed. There are various reasons for this failure.
First, it bas been estimated that over half o f the existing TB patients in developing countries are 
not covered by TB services; between 1988 and 1989, service coverage in Africa was estimated 
at 24% .! Second, at the peripheral level health workers often do not consider the diagnosis of 
TB in patients with a chronic cough, and patients may attend health units several times before 
a diagnosis is m ade.6,7 Third, patients may delay seeking medical advice and help because of 
other cultural beliefs; in this regard they may initially seek the help o f a traditional healer.
The traditional healer is an im portant and powerful member o f the local society, and most 
villages in Central and East Africa have at least one traditional healer who is easily accessible. 
There is little information available about the role o f the traditional healer in the diagnosis and 
management o f PTB, and we therefore decided to carry out a study.
Methods
Patients
A questionnaire study was carried out between November 1995 and February 1996 on sputum 
smear-positive PTB patients who had been adm itted to the TB ward o f queen Elizabeth Central 
Hospital, Blantyre, to receive supervised anti-TB chemotherapy. Questions concerning the use 
o f traditional healers (in Malawi, such healers deal both with herbs and evil spirits) were asked 
in the local language (Chichewa), and answers were entered into a questionnaire proforma. 
Information was entered into an EPI- IN FO  software package.
Traditional healers
Interviews were carried out with traditional healers living in Blantyre city. Traditional healers 
were asked about their knowledge o f cough and TB, their methods o f  diagnosis and manage­
m ent and the perceived outcome o f their treatment.
Results
Patients
During the study period 89 patients with smear positive PTB were admitted. There were 41 
men and 48 women, whose mean age (SD) was 31 (±9)  years. O f  these 33 (37%, 15 men and
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18 women) had received treatment from a traditional healer before seeking regular medical care. 
The length o f  time spent with the traditional healer ranged from two days to two years (medi­
an duration = four weeks).
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Table 1 Type o f  traditional medicine
Type of traditional treatment patients (%) Number of patients (%)
Herbal drink(s) alone 22 (67)
Herbal drink + bath 3 (9)
Herbal drink + bath + necklace 2 (6)
Root powder on tongue 4 (12)
Tattoos 1 (3)
Prayers 1 (3)
The type o f  traditional medicine taken by the patients is shown in Table 1. The majority of 
patients were treated with herbal drinks. Fourteen (43%) o f the patients paid no charge for tra­
ditional medicine; this was because the traditional healer stated he would only charge if the 
patient was cured. O f  the remaining 19 patients, seven (21%) paid less than one US$, eight 
(24%) paid 1-5 US$, two (6%) paid 6-15 US$ and two (6%) paid 16-30 US$. The outcome 
o f  traditional treatment is shown in Table 2. Twenty-four patients (73%) stated they did not 
improve or deteriorated on traditional treatment. The decision to seek regular medical care for 
the diagnosis and treatm ent o f PTB was made by the patient in 11 cases (33%), by the patient’s 
family in 12 cases (37%) and as a result o f advice from a health care worker in 10 cases (30%). 
In no case was the patient referred to the medical services by the traditional healer.
Table 2 Patient outcome with traditional medicine
Outcome Number of patients (%)
No better 19 (58)
Deterioration 5 (15)
Minimal improvement 5 (15)
Temporary improvement 4 (12)
Traditional healers
Seven traditional healers were interviewed, six men and one woman. They all knew about the 
disease tuberculosis, and the symptoms they m entioned ranged from cough, chest pains and 
paling hair to haemoptysis, weight loss and swelling o f limbs. Six o f  the healers believed that the 
cause o f TB was adultery in the household, but other causes were also mentioned: sexual inter-
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course, germs, stagnant water, alcohol abuse, wrong food, dust, and witchcraft. They all believed 
they could cure TB. Their treatments included ritual and herbal drinks, mainly (burned) roots, 
leaves, bark and twigs. The duration o f their treatm ent ranged from two weeks to two months 
(median four weeks). The charges for their treatm ent varied from a set charge o f  1.25 US$ to a 
variable charge depending on the am ount o f time and effort required for a cure. Four traditional 
healers said they would refer a patient to hospital if  their treatm ent did not cure the patient. In
1995, six o f the traditional healers claimed to have cured 116 patients with TB.
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Discussion
In this study, over one third o f smear-positive PTB patients adm itted to Queen Elizabeth 
Central Hospital, Blantyre, between November 1995 and February 1996 sought help from a 
traditional healer before approaching the medical services. The proportion o f patients may in 
fact be higher because patients can be hesitant in adm itting that they have taken traditional 
treatment for fear that the health staff would refuse to treat them. Patients who visited a tradi­
tional healer spent a median period o f four weeks taking traditional medicine; during this time 
almost three quarters o f the patients did not improve or deteriorated. This study o f course 
selected only patients who did not get better with traditional treatment. Those who were cured, 
if  any, would no t have been referred to a hospital or a health centre.
The delay in receiving standard anti-tuberculosis chemotherapy has two im portant conse­
quences. First, the patient may present in an advanced state o f the disease and this may con­
tribute to the high early mortality, which is seen in smear-positive PTB patients in Blantyre.8 
Second, the smear-positive patient is a transmitter o f  infection in the community, and is there­
fore a considerable public health risk up until the time adequate anti-TB treatm ent is started.
None o f  the smear-positive PTB patients had been referred to the medical services by the tra­
ditional healer, although two thirds o f traditional healers interviewed said that they would refer 
patients who were not improving. Because o f  the large num ber o f  traditional healers in the com­
munity, some o f  whom are very influential we believe it is im portant to involve this body of 
health care providers in the educational activities o f the National TB Control Programme 
(NTP). Traditional healers need to be taught to recognise illnesses such as TB, which in our 
opinion they should not treat unless there is proven anti-tuberculosis efficacy o f  the treatment, 
which they administer. It is prudent to keep an open m ind on this issue. There are strong calls 
from all parts o f the globe about the need for new drugs for TB, and in this study over 100 
patients in 1995 were claimed by the traditional healers to have been cured by traditional med­
icine.
Traditional healers
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Case seeking behaviour
Summary
Setting: Government hospitals in five districts in Malawi.
Objective: To determine care seeking behaviour and diagnostic processes in patients newly diag­
nosed with smear-positive pulmonary tuberculosis (PTB).
Design: Structured questionnaires completed by interview between January to September 
1998.
Results: During the study period 1518 patients were registered with PTB o f whom 1099 (72%) 
were interviewed. The median delay between onset o f cough and diagnosis was 8 weeks. There 
was a variable pattern o f care seeking behaviour, w ith 70%  o f patients initially visiting a place 
o f  orthodox medical care and 30% visiting traditional healers, grocery shops, etc. O f  these, 867 
(79%) patients had one or more subsequent contacts for help, w ith these visits targeted more to 
orthodox medical care. A t all stages, antibiotics resulted in symptomatic improvement in up to 
40%  o f cases. There was a median time o f 7 weeks between cough and first submission o f spu­
tum  specimens. Almost all patients received sputum  smear results after a median length o f 4 
days; 474 (43%) o f patients were only aware o f their diagnosis at the time o f  receiving smear 
results, this observation being significantly associated with lack o f schooling and no t knowing 
o f  another person with TB.
C onclusion: More needs to be done to educate communities and non-orthodox care providers 
about the diagnosis and treatment o f TB.
Introduction
T W O  OF T H E  KEY components o f a good tuberculosis (TB) control programme are early 
diagnosis and prom pt institution o f effective treatment. This is especially im portant in patients 
with smear-positive pulmonary tuberculosis (PTB) in order to try and reduce the transmission 
time o f Mycobacterium tuberculosis in the community. Studies carried out in G hana1 and 
Botswana2 have shown long median delays o f 3-4 months between onset o f symptoms and diag­
nosis in patients with PTB. The principal reasons for delay are patients seeking alternative ways 
o f  treating their cough and the health services failing to perform sputum  examination.
Since 1984, the National TB Control Programme (NTP) in Malawi has been supported by the 
International Union Against Tuberculosis and Lung Disease (IUATLD), and follows guidelines 
from the IUATLD3 and the W orld Health Organization .4 Case detection is based on passive 
case finding using sputum  smear microscopy as the first-line investigation in a suspect with 
PTB. In line with the studies in G hana1 and Botswana,2 a study in Malawi in 1988 amongst 
patients w ith smear-positive PTB also found a median delay o f  4 months between onset o f 
cough and diagnosis.5 Docum ented reasons for this delay included prior consultation with tra­
ditional healers in over 50% o f patients, and a large num ber o f attendances at health centres
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before sputum  examination was performed. Operational research on case finding activities in 
Malawi between 1995 and 1996 revealed that many health care staff did not adhere to guide­
lines on screening PTB suspects,6’7 and confirmed that a large proportion o f smear-positive 
PTB patients had visited a traditional healer before seeking regular medical care.8 From 1997 
onwards, intensive efforts were made in all districts to train hospital and health centre staff to 
obtain sputum  specimens in patients with a cough for longer than 3 weeks. Efforts were also 
made to 1) inform the general population about TB with educational talks on the radio, posters, 
TB messages painted on buses and TB-sponsored football matches, and 2) to brief traditional 
healers about TB at zonal health centre meetings. One year later, and with training and educa­
tional initiatives still on- going, we were interested to obtain up-to-date inform ation about care 
seeking behaviour and diagnostic processes in patients w ith smear-positive PTB.
Methods
Setting
The government hospitals responsible for diagnosis and treatment o f TB cases in five districts 
in Malawi were chosen as study sites. There were three hospitals in the Southern region (Queen 
Elizabeth Central Hospital, Blantyre; Zom ba Central Hospital, Zomba; and Mangochi District 
Hospital), one in the Central region (Ntcheu District Hospital) and one in the Northern 
Region (Mzimba District Hospital).
Patients
Between 1 January 1998 and mid-September 1998, all patients newly registered with smear- 
positive PTB at each o f the five hospitals were to be interviewed by one o f the TB programme’s 
clinical research officers. Structured questionnaires were completed by interview in the local lan­
guage or English shortly after diagnosis (up to 2 weeks). The questionnaire for each patient 
included questions about age, sex, TB registration number, history o f  previous TB treatment, 
duration o f illness and cough, details o f first contact for management o f the illness, the 
num ber o f  all subsequent contacts and details o f  management, the time interval between onset 
o f cough and first submission o f  sputum  specimens for smear microscopy, details o f the process 
o f receiving results o f sputum  smear examination, other investigations carried out, and general 
questions about schooling and about the patient’s knowledge o f other people ill with TB. Data 
on patient visits to government and mission hospitals were combined, because at both types of 
health facility there is a policy o f not charging patients with TB.
W hen all questionnaires were completed, the TB registration numbers o f  all patients registered 
with new smear-positive PTB during the study period were compared with the TB registration
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numbers o f those interviewed in order to determine the proportion o f patients who were inter­
viewed.
Analysis
D ata from each hospital were entered into Epi-Info version 6.0 software. %2 test was used to 
assess differences in proportions, with differences at the 5% level being regarded as significant. 
Odds ratios (OR), their 95% confidence intervals (CI) and P values were also calculated where 
appropriate.
Results
Patients interviewed and clinical features
During the 8-9 m onth period, a total o f 1518 new patients with smear-positive PTB were 
registered at the five hospitals: 575 in Blantyre, 451 in Zomba, 228 in Ntcheu, 183 in Mangochi 
and 81 in Mzimba. Interviews were conducted in 1114 (73%) patients: this comprised 318 
(55%) patients in Blantyre, 356 (79%) in Zomba, 223 (98%) in Ntcheu, 154 (84%) in Mangochi 
and 63 (78%) in Mzimba. Reasons why patients were not interviewed were not specifically 
documented, but included death, early discharge from hospital and absconding. Fifteen patients 
who were interviewed were subsequently excluded from analysis: seven adm itted to a previous 
episode o f  TB, five on checking with the TB register had smear-negative PTB or extra- 
pulmonary TB and three had virtually no inform ation recorded in the questionnaire. 
Questionnaires were thus analysed for 1099 patients (72% o f those registered).
There were 522 males and 577 females, with a mean age o f 33 years (range 9-80 years). The 
median duration o f  illness was 10 weeks (range 2-100 weeks). The three commonest presenting 
symptoms o f illness were cough (61%), fever (16%) and chest pain (11%). All patients eventu­
ally developed a cough. The median duration o f cough prior to diagnosis was 8 weeks; 565 
(52%) patients had a cough for 8 weeks or less, while 534 (48%) had a cough for longer than 
8 weeks.
First contact for help
The places o f first contact for help and associated care seeking behaviour are shown in Table 1: 
70%  o f patients visited a place providing orthodox medical care, while 30% visited places prac­
tising non-orthodox care (i.e. traditional healers, grocery shops, local vendors, etc). The deci­
sion about where to go for help was made solely by the patient in 494 (45%) cases; it was influ­
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enced by a close family member (parent, sibling, spouse or partner) in 261 (24%) cases, and 
influenced by a health care worker in 219 (20%) cases. The commonest reason for attending 
the place o f first contact was because it was the nearest place to home (603 patients, 55%), with 
the other main reason being a good reputation, pleasant reception and strong medicine (320 
patients, 29%); 57% o f patients who visited a traditional healer, grocery shop or a vendor and 
55% o f those who visited a health facility stated that this was because it was the nearest place 
to home. M ost patients (753, 69%) walked to the place o f first contact, w ith others going by 
bus/mini-bus (18%), bicycle (10%) and m otor car (3%). The main way o f getting to the near­
est place o f contact was by walking in 81% o f patients: 89% o f patients who first visited a tra­
ditional healer, grocery shop or a vendor walked compared with 62% o f patients who visited a 
hospital or health centre. Most patients (701, 64%) received pills, but did not know the names 
or types o f pills, which they were given; 112 (10%) patients knew they had been given an antibi­
otic and 150 (98%) patients attending a traditional healer reported that they were given herbal 
medicine. Payment was made for treatment by 461 (42%) patients, the median payment made 
being the equivalent o f  1.4 US$ (range a few cents to 24 US$). Payment was made by 51 (9%) 
patients visiting a government/mission health facility, 158 (86%) patients visiting a private clin­
ic and 252 (77%) patients visiting non-orthodox facilities. In 265 patients (24%) the cough 
improved with the treatm ent received - 240 o f these patients stated that the cough returned a 
median o f 3 weeks later. There was only one contact for help in 232 (21%) patients, at which 
point patients were referred for sputum  examination. This occurred in 167 patients attending 
health centres, 45 attending hospitals, 10 attending private clinics, six attending traditional 
healers and four attending other places.
Table 1 Place o f first contact for help in patients with smear-positive pulm onary tuberculosis
Patients at each place o f contact (%) who
Place o f first contact
Number (%) 
of patient 
in study
Visited 
because 
it was 
nearest Walked
Paid for 
treatment
Found cough
improved
with
treatment
Government/mission
health centres 433 (39) 65 70 8 31
Private clinic 183 (17) 42 56 86 28
Government/mission
Hospital 157 (14) 44 45 11 18
Traditional healer 153 (14) 48 83 58 6
Grocery/local vendors 145 (13) 67 94 99 20
Other 28 (3) 18 46 71 43
Total 1099 55 69 42 24
Case seeking behaviour
Subsequent contacts for help
A total o f 867 patients had a median o f one further contact for help before a diagnosis o f TB 
was made (range 1-15 contacts), while 262 (24%) patients had three or more further contacts. 
Details o f these contacts are shown in Table 2. O f  the 2078 contact visits, 1553 (75%) were to 
health centres or hospitals, and relatively fewer visits at this stage were made to traditional heal­
ers (8%), private clinics (8%) and other sites such as groceries, small dispensaries or private 
pharmacies (9%). Three hundred and thirty-eight patients did no t know what treatm ent they 
had received; 529 patients knew they had been given an antibiotic at one o f these visits (the 
antibiotic was known to be co-trimoxazole in 250 patients, penicillin in 103 and doxycycline in 
2 2 ), and these patients took a total o f 841 courses o f  antibiotics; 204 (39%) patients receiving 
an antibiotic reported some improvement in the cough.
Table 2 Subsequent contacts for help in patients w ith smear-positive pulm onary tuberculosis
Number of visits to
Place o f contact Number of patients each place of contact
Government/mission health centres 370 718
Private clinic 125 162
Government/mission hospital 556 835
Traditional healer 93 166
O ther (includes pharmacy, grocery store, etc) 137 197
Total 1281 2078
N o te : M a n y  p a tie n ts  v is ited  tw o  o r m o re  d iffe ren t places o f  c o n ta c t fo r  h e lp , w h ic h  is w h y  th e  n u m b e rs  d o  n o t  a d d  u p  to  867 .
Diagnosis o f smear-positive PTB
There was a median time o f  7 weeks between onset o f cough and first submission o f sputum  
specimens for smear examination. The time was less than 3 weeks in 144 (13%), 3 to 8 weeks 
in 534 (49%), and longer than 8 weeks in 421 (38%) patients. Information on sputum  smear 
results were given to 1074 (98%) patients after a median length o f  4 days (range 1-49 days) 
from sputum  submission. One set o f sputum  specimens was obtained from 941 (86%) patients 
(a set o f sputum  specimens is defined as an on-the-spot sputum , an early m orning sputum  and 
a second on- the-spot sputum), 126 (12%) gave two sets, 26 (2 %) gave three sets and six gave 
four or more sets. During the diagnostic process chest radiography was carried out in 151 (14%) 
patients.
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Patient’s knowledge about PTB and other related aspects
Six hundred and twenty-five patients (57%) believed that they might have PTB before the diag­
nosis was made, while 474 (43%) were only aware o f the diagnosis when they received their spu­
tum  smear results. Details o f  when the patients thought they had PTB in relation to schooling 
history and knowing other people with TB are shown in Table 3. Lack o f  schooling (O R 2.10, 
95% CI 1.60-2.77, p < 0.05) and not knowing another person with tuberculosis (O R 1.77, 
95% CI 1.38-2.28, p < 0.05) were significantly more frequent in patients who were only aware 
o f their diagnosis o f PTB at the time o f sputum  smear results compared with those who believed 
that they m ight have PTB before the diagnosis was made. Knowing another person with TB was 
more common in patients interviewed at the two central hospitals in Blantyre and Zom ba 
(478/666 = 72%) compared with patients interviewed at district hospitals (164/ 433 = 38%, 
p < 0.05). O ther people known to have TB included a family member or spouse in 387 (60%), 
a friend in 217 (34%) and a workmate in 38 (6%) cases. O f  other persons known to have TB, 
54% were said to be well, 15% were ill, 26%  had died, and there was no information in the 
remainder.
Table 3 Patients’ knowledge about pulm onary TB in relation to schooling history and knowing others 
affected with TB
Patient’s knowledge about pulmonary tuberculosis
Belief that PTB was Only aware o f diagnosis
the cause of illness after results o f sputum
before sputum smear results smear examination
Number o f patients 625 474
Number (%) of patients with*
No school attendance 137 (22) 176 (37)
School attendance 488 (78) 298 (63)
Primary school only 359 220
Secondary school 129 78
Number (%) of patients who*
Knew another person with TB 403 (64) 239 (50)
* Percen tage  o f  p a tie n ts  w ith in  each  k n o w led g e  ca tego ry  (i.e., believed  th a t  th e y  h a d  P T B  befo re  receiv ing  s p u tu m  resu lts o r w ere on ly  aw are o f 
diagnosis a lte r s p u tu m  resu lts).
Discussion
This study shows that in a large num ber o f  patients newly diagnosed with smear-positive PTB 
the median time between onset o f cough and diagnosis was 8 weeks. N ot all consecutive patients 
were interviewed according to the study protocol. Some patients died before interview, and in 
some cases the interviews were not carried out before the patient left hospital. The proportion
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o f patients interviewed was lower at the central hospitals due to the larger numbers o f  patients 
and the fact that clinical research officers had other duties to perform. Nevertheless, nearly 
three-quarters o f  all patients had their questionnaires evaluated. Sites were chosen so that all 
three regions in the country and urban district areas were represented, and we feel the results are 
a reflection o f the current situation at country level.
The pattern o f  care seeking behaviour was variable. Approximately 70%  o f patients initially 
visited a place o f orthodox medical care and 30% visited traditional healers, grocery shops, local 
vendors, etc. In over half o f the patients the commonest reason for choosing the first place of 
contact was proximity to home, reflected in the fact that most patients walked to seek help. 
Close to 80% o f the population in Malawi are said to live within 8 km o f  a health service point,9 
and over half o f  the patients who visited a health facility as their first contact gave proximity to 
home as the main reason for their visit. Unfortunately, we did not docum ent distance from 
home to first point o f contact. However, a distance o f up to 8 km, making a round trip o f  up 
to 16 km, is still a significant barrier to access if patients are ill and have to walk.10 Payments 
were made by over 75%  o f patients who visited private clinics and places o f non-orthodox 
medical care. O ther costs, which were not docum ented in this study, include the paym ent for 
some form o f engine-driven transport and loss o f earnings from time spent away from work; 
these may also adversely affect access to care.10 Most patients received pills o f some sort, and 
either did not know or did not remember the names or type o f  these medications. However, in 
about one quarter o f  patients the cough improved, only to return some time later.
For patients who had more than one visit before a diagnosis o f PTB was made, these visits were 
targeted more towards orthodox medical care. At this stage a large num ber o f patients remem­
bered being given an antibiotic, and over one third o f patients reported an improvement again 
in their cough. It bas been noted in other studies that patients with microbiological TB can lose 
their respiratory symptoms after a course o f antibiotics;11 this may be due to same antibiotics 
having a short mycobacteriostatic action or because o f bacterial superinfection.12 W hatever the 
reason, symptomatic improvement after an antibiotic may contribute to a delay in diagnosis, as 
bas been found in other parts o f  sub-Saharan Africa.13
At present the N T P  spends time and resources in educating traditional healers about TB. This 
study confirms the importance o f traditional healers, although fewer patients adm itted visiting 
traditional healers in this study compared with previous reports from Malawi.5,8 This study also 
shows that patients visit grocery shops, local vendors and private clinics, and that in future it 
will be im portant to include these personnel in TB education. Experience in rural Nigeria with 
patent medicine vendors has demonstrated that training in primary care medicine can signifi­
cantly improve the health care knowledge and behaviour o f  non-medically trained personnel.14 
W hile in general the diagnostic process o f sputum  examination worked well, a substantial num ­
ber o f patients still had cough present for more than 8 weeks before they submitted their first 
set o f sputum  specimens. W hen sputum  samples were submitted, most patients received their 
results within an acceptable time frame. We were pleased to see that few patients had a chest 
radiograph, w ith the diagnostic effort being concentrated on sputum  smear examination.
C H A P T E R  V
Despite efforts at informing the public about TB, over 40%  o f patients only realised the diag­
nosis when told the results o f their sputum  smear examination. Lack o f  schooling and not 
knowing another person with TB were associated with a lack o f realisation o f  the diagnosis. 
There are initiatives underway in Malawi to inform schoolchildren about im portant medical 
conditions such as AIDS, TB and malaria, but it is obviously equally im portant to target rural 
people and villagers who may not have access for one reason or another to school education. 
There needs to be more use o f posters, talks and radio broadcasts on a regular basis; widespread 
coverage o f TB issues on W orld TB day is another practical way o f informing communities 
about TB.
Tuberculosis is a common disease; 642 (58%) patients knew o f another person with TB, most 
commonly a family member. Knowing another person with TB was also more common in the 
city environment o f  Blantyre and Zomba, which probably relates to overcrowding, urban pover­
ty and higher prevalence o f H IV  infection and AIDS .15 There is growing evidence that a sig­
nificant num ber o f  new cases o f  TB in sub-Saharan Africa result from recent transmission and 
casual contact,16,17 in which case delays between onset o f symptoms and diagnosis and treat­
m ent should not be tolerated. Although we can be pleased that the median delay between onset 
o f cough and diagnosis in this study was 8 weeks, rather than 4 months as found previously,5 
there are no grounds for complacency, as TB transmission can still occur during this time 
period. There is also evidence that delay in the diagnosis o f TB may compromise the chances of 
individual cure. Untreated TB in HIV-infected persons may accelerate the decline in immuno- 
competence18 and the progression to severe immunodeficiency, and may allow the development 
o f extensive pulmonary tuberculous disease.
One o f the im portant components o f  global TB control is involvement o f communities in treat­
m ent and case holding. However, communities should also be involved in case finding .19 It 
is unlikely that resource-poor countries will find the resources to change their case detection 
strategy from passive to active case finding. Therefore, ways to improve passive case finding need 
to be found. More suspects who never reach treatment need to be identified, and o f  those who 
reach treatment the time between onset o f  symptoms and diagnosis needs to be shortened. More 
dialogue between the TB programme and other im portant stakeholders such as traditional heal­
ers, village headmen, schoolteachers and patients who are responding well to treatment should 
be undertaken if  we are to improve our case detection rates and reduce the delays in diagnosis.
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Chapter VI
Viability o f stored sputum 
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Summary
A laboratory study was performed to determine how long sputum  specimens from smear-posi­
tive tuberculosis patients can he stored at room temperature or in the refrigerator and retain a 
positive acid-fast bacilli (AFB) smear or a positive mycobacterial culture. Sputum samples from 
30 patients were examined up to 4 weeks and samples from 13 patients examined up to 8 weeks. 
Provided samples had not dried out, all sputum  smears remained AFB positive up to 4 and 8 
weeks. In both patient groups, at 4 weeks 37-39% o f specimens at room temperature grew 
mycobacteria compared with 54-67% o f specimens stored in the refrigerator. These results have 
implications for tuberculosis programme policy.
Introduction
In Malawi, sputum  specimens submitted at rural health centres are transported to hospital 
laboratories for smear examination. Logistical difficulties can lead to delays in getting sputum 
examined. Long sputum  storage times may result in false-negative sputum  smears.1-3 Sputum 
specimens are also subm itted to the central mycobacterial reference laboratory for culture for 
patients with previously treated smear-positive pulmonary tuberculosis (PTB) in order to deter­
mine drug sensitivity patterns which may influence the choice o f drugs for the continuation 
phase o f treatment. There are often delays in transporting specimens from district hospitals to 
the central reference laboratory, and this can lead to loss o f  culture viability.2-5 
We designed two studies to examine how long sputum  specimens can be stored, either at room 
temperature or in the refrigerator, before losing their acid-fastness for smear microscopy or their 
culture viability.
Methods
Patients and study methodology
Patients with smear-positive PTB registered at Queen Elizabeth Central Hospital, Blantyre, 
were asked to subm it two further sputum  specimens into containers before commencing treat­
ment. These specimens were processed on the day o f submission (day 0). Thereafter, one spu­
tum  container was stored in the refrigerator at 4°C and one at room temperature (20°- 25°C). 
In the first study (Study 1), the refrigerated and room temperature sputum  specimens were 
processed for smear microscopy and mycobacterial culture on days 2, 4, 7, 9,11,14,21 and 28. 
W hen results were obtained for Study 1, a second study (Study 2) was conducted with smaller 
numbers o f  patients in which duration o f sputum  storage was extended up to 8 weeks, with 
smear and culture examinations performed on a weekly basis.
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Smear and culture examination
Sputum smears were examined for acid-fast bacteria (AFB) using Ziehl-Neelsen stain .6 For 
mycobacterial culture, each specimen was decontaminated by sodium hydroxide before inocu­
lation into Lowenstein- Jensen (L- J) slopes: examination was at weekly intervals for up to 8 
weeks.7
Observer variability
There were two technicians involved in the laboratory. Observer variability in smear microscopy 
and culture was tested using nine portions o f sputum  from each o f three patients (AFB 3+, AFB 
2+ and AFB negative). There was no intra- or inter-observer variability in smear or culture 
results.
Statistical analysis
Differences in culture viability at defined times and between refrigerated and room-temperature 
specimens were assessed using X2 test w ith Yates correction and X2 test for trend. Differences at 
the 5% level were regarded as significant. Odds ratios (OR), 95% confidence intervals (CI) and 
p values were also calculated.
Results
Study 1
There were 30 patients: 10 with 3+ AFB, 10 with 2+ AFB and 10 with 1+ AFB. If specimens 
did not dry out, all those that could be processed remained smear-positive on each examination 
day from the day o f submission up to 28 days o f storage, either at room temperature or in the 
refrigerator. Results o f sputum culture-positivity are shown in Table 1. There was a gradual decline 
in culture-positivity up to 28 days o f storage for both room-temperature and refrigerated 
specimens. A significantly higher proportion o f refrigerated specimens were culture-positive at 
14 days (OR = 4.0, 95% CI 1.1-4.9, p = 0.03) and culture- positive at 28 days (O R = 3.4, 
95% CI 1.1-11.6, p = 0.04) compared with room-temperature specimens.
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Table 1 Sputum cultures up to 28 days after sputum  submission
Positive sputum cultures for M. tuberculosis
Initial AFB Storage of No. of Day 0 Day 7 Day 14 Day 21 Day 28
smear result sputum specimens n (%) n (%) n (%) n (%) n (%)
3+ Room 10 10 9 4 2 3
Refrigerator 10 10 10 8 8 9
2+ Room 10 10 9 5 7 5
Refrigerator 10 10 10 9 8 7
1 + Room 10 10 8 6 3 3
Refrigerator 10 9 9 7 4 4
Combined Room 30 30 (100) 26 (87) 15 (50) 12 (40) 11(37)
AFB smears Refrigerator 30 29 (97) 29 (97) 24 (80) 20 (67) 20 (67)
(3+,2+,1+)
T w o o f  5 4 0  s p u tu m  cu ltu re s  b ecam e co n tam in a ted .
Study 2
There were 13 patients: six with 3+ AFB, five with 2 + AFB and two with scanty AFB. Results 
for smear- positivity and culture-positivity for all patients combined are shown in Table 2. 
Sputum smears were all positive up to 4 weeks. By 8 weeks three specimens had dried out but 
the remaining 10 specimens were still smear-positive. There was a general decline in sputum  
culture-positivity, similar to that found in Study 1. A t 4 weeks, positive cultures were found in 
five (39%) room-temperature specimens and seven (54%) refrigerated specimens. At 8 weeks, 
positive cultures were found in three (23%) room-temperature specimens and six (46%) refrig­
erated specimens. These differences were not statistically significant.
Table 2 Sputum smear and sputum  culture results up to 8 weeks after sputum  submission
Weeks from submission of sputum specimen
Storage of ---------------------------------------------------------
Type of specimen sputum 0 1 2 3 4 5 6 7 8
Sputum smears positive for AFB Room 13 13 13 12 3 12 12 12 10
Refrigerator 13 13 13 13 13 12 12 12 10
Sputum cultures positive for Room 10 9 8 5  5 2 2 6 3
M. tuberculosis Refrigerator 8 1 0 1 0 6  7 6 5 8 6
S p u tu m  spec im ens w ere e x am in ed  fo r  1 3  p a tie n ts : 1  s p u tu m  sp ec im en  b ecam e  d ry  a t 6  w eeks, 3  s p u tu m  spec im ens b ecam e d ry  a t 8 w eeks, 5  o f  
2 3 4  s p u tu m  cu ltu re s  b ecam e co n tam in a ted .
A FB  =  acid-fast bacilli
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Discussion
Results show that in a laboratory environm ent in Malawi all sputum  specimens (whether stored 
at room temperature or in the refrigerator) that could be processed remained smear-positive for 
AFB up to 4 weeks in the first and second studies, and up to 8 weeks in the second study. The 
major threat to smear microscopy was in the sputum  specimen drying out, and this may have 
been a result o f the study design which involved opening and shutting sputum  containers on 
prescribed days in order to obtain portions o f  sputum  for examination.
Mycobacterial culture viability declined with time, although the ability to grow mycobacteria 
was better for specimens kept in the refrigerator than at room temperature. In both studies, at 
4 weeks between 37-39%  o f specimens kept at room temperature could grow mycobacteria 
compared with 54- 67% o f specimens stored in the refrigerator. At 8 weeks, the ability to grow 
mycobacteria had declined to less than 25%  for room-temperature specimens and less than 50% 
for refrigerated specimens. The decline in mycobacterial culture viability was not constant, par­
ticularly in Study 2, which probably reflects observer variability in sampling portions o f sputum 
and in decontaminating specimens. In both studies, the proportion o f contaminated cultures 
was small, probably reflecting a rather harsh decontamination process.
This study has implications for the Malawi National Tuberculosis Control Programme. First, 
specimens for smear microscopy which arrive late in hospital laboratories from health centres 
should not be automatically discarded by laboratory technicians. Smears can still be positive 
even if sputum  bas been stored for up to 8 weeks. Second, sputum  specimens sent to the 
mycobacterial central reference unit for culture and sensitivity should be kept in a refrigerator 
prior to transportation. W hile it is better to avoid delay, at least 50% o f refrigerated specimen 
may show mycobacterial growth even if  the delay is up to 4 weeks.
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strategies to intervene with appropriate 
antibiotics early on in the clinical event. 
Early recognition of pneumococcal and 
salmonella sepsis is the key to a 
reduction in early mortality from HIV-1 
infection.
Richard Brindle
Public Health Laboratory, S t Mary’s  Hospital, 
Portsmouth P03 6AQ. UK
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Sir—Xavier Anglaret1 and Stefan 
Wiktor2 and their colleagues believe 
that co-trimoxazole prophylaxis in 
HIV-infected patients may not be 
applicable to all parts of Africa, because 
of differences in the patterns of incident 
infections and of co-trimoxazole 
sensitivity of major bacterial pathogens 
such as non-typhoidal salmonellae 
(NTS) and pneumococci. We share this 
view. The investigators report in-vitro 
co-trimoxazole resistance rates of 14% 
in NTS isolates in Abidjan. In patients 
admitted to hospital in Blantyre, 
Malawi, the most common causes of 
invasive bacterial disease in HIV- 
infected adults are NTS and 
pneumococci, of which the in-vitro 
resistance rates to co-trimoxazole in the 
past year have been 83% and 91%, 
respectively (unpublished data).
In Malawi and some other African 
countries where malaria is a major 
cause of morbidity and mortality, 
sulphadoxine-pyrimethamine is the 
first-line treatment for Plasmodium 
falciparum infections. In many countries 
it is a back-up treatment when 
chloroquine fails. Parasites resistant to 
sulphadoxine-pyrimethamine are 
becoming more prevalent.3 Laboratory 
data indicate that cross-resistance may 
exist between pyrimethamine and 
trimethoprim, and that the widespread 
use of co-trimoxazole could contribute 
to the selection or spread of 
sulphadoxine-pyrimethamine-resistant 
P falciparum.
What is best in West Africa may not 
have the same benefits elsewhere on the 
continent. In many countries, 10-25% 
of adults are HIV seropositive. A policy 
of co-trimoxazole prophylaxis carries 
enormous logistical and cost 
implications. Its effects on the drug- 
responsiveness of P  falciparum and 
invasive bacteria are unknown. It is all
the more important that placebo­
controlled trials are conducted in areas 
with high bacterial co-trimoxazole 
resistance, with attention to the possible 
impact on malarial sensitivity to 
sulphadoxine-pyrimethamine, before 
co-trimoxazole prophylaxis is 
introduced widely in Africa.
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Sir—Co-trimoxazole prophylaxis in 
patients infected with HIV-1 prevents 
Pneumocystis carinii pneumonia (PCP),1 
a major cause of morbidity and 
mortality among AIDS patients in 
developed countries.2 This intervention 
is not widely used in sub-Saharan 
Africa where PCP is uncommon.3'4 
However, co-trimoxazole also prevents 
other opportunistic infections that 
occur commonly in patients with 
HIV-1 infection in Africa.4 We read 
with interest Stefan Wiktor and 
colleagues Cote d’Ivoire trial5 that 
showed the drug improved the outcome 
of HIV-1-associated tuberculosis.
We assessed the effect of co- 
trimoxazole on the incidence of 
opportunistic infections and survival of 
HIV-l-infected adults with tuberculosis 
who presented to our HIV clinics 
between January, 1992, and December,
1996. During this period, we recruited 
a prospective cohort of patients for 
whom demographic, clinical, and 
laboratory data were recorded. 
Prophylactic co-trimoxazole was not 
used widely at first because efficacy of 
the drug was thought to be limited to 
prevention of PCP. Subsequently, 
480 mg daily was given if the CD4+ cell 
count was less than 200 cells/ L. The 
case definition of tuberculosis was 
positive culture or a compatible clinical 
picture combined with a positive smear 
or a histological diagnosis. Follow-up
was the time from the diagnosis of 
tuberculosis to December, 1996, which 
was the date of last visit before 
the study endpoint, or to death. 
Survival was assessed by the Kaplan­
Meier method. Cox’s proportional 
regression hazards model was fitted 
to adjust for differences at baseline.
158 patients fulfilled the case 
definition of tuberculosis. Co- 
trimoxazole was used by 71 patients. 
The incidence of opportunistic 
infections (PCP, cerebral toxoplas­
mosis, non-typhoid salmonellosis, and 
bacterial pneumonia) that could be 
prevented by co-trimoxazole was lower 
in the treatment group than in the 
controls (three patients, incidence 
density 0-3 per 100 person-months 
vs 14 patients incidence density 2-1 
per 100 person-months; risk ratio 
0-23 [95% Cl 0-06-0-84]; p=0-017). 
Mortality was also lower in the 
treatment group than in the controls 
(14 patients, 1-2 per 100 person- 
months vs 36 patients, 5-5 per 100 
person-months; p=0-002). The median 
survival of the co-trimoxazole group 
was better than that of the controls 
(28 vs 16 months; p=0-03). In the 
univariate analysis, use of co- 
trimoxazole improved survival (risk 
ratio 0-53 [0-30-0-94]; p=0-03). A 
similar protective effect was found after 
adjustment for differences at baseline 
(0-38 [0-23-0-62]; p<0-001). It is 
noteworthy that the better outcome in 
patients given co-trimoxazole was 
achieved despite their lower CD4+ 
lymphocyte count at baseline (median 
174 [IQR 33-199] vs 308 [290-745] 
cells/ L; p<0-001).
Our findings together with those of 
Wiktor and colleagues® indicate a 
dramatic benefit of prophylactic co- 
trimoxazole in HIV-l-infected patients 
with active tuberculosis and confirm 
that the lower dose of 480 mg daily 
is also effective in an African context.1 
All patients with tuberculosis should 
thus be offered HIV testing. Co- 
trimoxazole is an affordable 
intervention that would help improve 
the therapeutic nihilism which 
surrounds HIV in many African 
countries.
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Chapter VIII
Efficacy and safety of two different dosages of 
cotrimoxazole as preventive treatment for H IV  
infected adults with smear positive pulmonary 
tuberculosis in Blantyre, Malawi; 
a randomised clinical trial.
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Cotrimoxazole prophylaxis
Summary
Background: UNAIDS provisionally recommended the use o f cotrimoxazole (CTX) prophy­
laxis in patients with HIV/AIDS in sub-Saharan Africa as a simple and cheap intervention to 
reduce the high m ortality rates. The efficacy o f such a prophylaxis was shown particularly in 
HIV-positive smear positive pulm onary tuberculosis (PTB) patients in Ivory Coast, and this has 
made it ethically difficult to justify further efficacy studies using placebo controls. However, fur­
ther work is needed in this area, and we conducted a study to assess the efficacy and safety of 
two different dosages o f C TX  in prophylaxis in similar patients in Blantyre, Malawi.
M ethods: The design o f  the study was a randomised, double-blind trial using two dosages 
(480 mg and 960 mg) o f cotrimoxazole given to 272 and 307 new HIV-positive smear-positive 
PTB patients, respectively. Patients were followed up for a median o f 14.5 months. The prima­
ry outcome was survival, and the outcome in the two groups was also compared with the out­
come observed in a) an unselected cohort o f HIV-positive, new smear-positive PTB patients 
registered in Zomba, Malawi in 1995 and b) new smear-positive PTB patients registered in the 
Malawi National Tuberculosis Programme (NTP) in 1999. The secondary outcome was the 
occurrence o f  (opportunistic) events, especially bacterial pneumonia.
Findings: There were no statistical significant differences in m ortality and bacterial pneum onia 
in the groups receiving the two different dosages. The case fatality rate at the end o f the PTB 
treatm ent (8 months) was 15.4% in the CTX  480 mg group and 14.0% in the CTX  960 mg 
group (p = 0.63). This was lower (though not significantly) than the case fatality rate in the 
Zom ba cohort (19.2%, p = 0.10) and lower than the case fatality rate o f the N TP 
(21.0%, p < 0.001). CTX  was well tolerated, and only one patient had to stop prophylaxis 
because o f a serious side effect. Compliance was fair w ith 2.5%  o f the patients being non-com- 
pliant and 7.8%  o f the patients defaulted from the study.
In terp reta tion : This study provided circumstantial evidence that cotrimoxazole prophylaxis 
may have a beneficial effect on m ortality and m orbidity in H IV  infected smear positive PTB 
patients. However, our results should be interpreted with caution because o f  methodological 
differences with the cohort group in Zom ba and the data from the NTP. The efficacy o f a 
dosage o f 480 mg C TX  was not significant different from a dosage o f 960 mg. Both dosages of 
cotrimoxazole were well tolerated, and the intervention is cheap and easy to implement. These 
results would support implementation o f C TX  in this patient group until better strategies are 
available or evidence is convincingly presented to suggest that its benefit is marginal.
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Introduction
The m ortality in sub-Saharan Africa o f patients who are treated for tuberculosis has increased 
dramatically in the last decades due to HIV .1 There is an urgent need for measures to reduce 
this mortality. At present, the availability o f  antiretroviral treatm ent in Africa is limited. 
Cotrimoxazole (CTX) prophylaxis has several potential benefits. Before the introduction of 
antiretroviral therapy in the industrialised world CTX  prophylaxis was widely used in H IV  
infected patients with impaired immunity. The decrease in m orbidity and mortality was m ain­
ly due to preventing opportunistic infection with Pneumocystis carinii.2 In Africa, the reported 
incidence o f Pneumocystis carinii pneum onia (PCP), is m uch lower.3-5 However, CTX  prophy­
laxis may still be effective in decreasing m ortality and morbidity through the prevention o f other 
CTX  susceptible (opportunistic) infections.
This assumption was based on existing knowledge o f the causes o f m ortality and morbidity in 
H IV  infected patients in Africa. Mortality is high because o f  fatal bacterial infections with 
Streptococcus pneumoniae and non-typhoidal salmonellae (NTS).6-8 O ther causes o f death and 
serious illness include cerebral infections with Toxoplasma gondii9,10 and chronic diarrhoea 
caused by Cryptosporidium parvum, Isospora belli and Cyclospora cayetanensis.11 Evidence from 
studies in the industrialised world showed that the incidence o f pneumococcal disease and 
Toxoplasma encephalitis was lower in patients who received CTX  prophylaxis for PCP.12,13 
Furthermore, there is a known, recently confirmed,14 beneficial effect o f C TX  on Plasmodium 
falciparum.
This led to trials to assess the efficacy o f C TX  in Africa. In Ivory Coast, the use o f  cotrimoxa- 
zole (CTX) prophylaxis decreased m ortality in patients with tuberculosis by 46% .15 In H IV  
positive patients w ithout tuberculosis there was no reduction in mortality, but a 43%  reduction 
in hospital admissions.16 In Senegal,17 a study in H IV  positive patients w ithout tuberculosis 
showed no beneficial effect, bu t had small numbers o f patients. In a recently completed study 
in Thyolo district, Malawi, cotrimoxazole showed a significant reduction in m ortality in HIV- 
positive patients with smear-negative PTB and extrapulmonary TB, but not in smear positive 
PTB .18 The results o f the Ivory Coast study have lead to the provisional recommendation of 
W H O /U N A ID S that “CTX  should be used for prophylaxis in adults and children living with 
HIV/AIDS in Africa as part o f  a m inim um  package o f care”.19 These recommendations have 
made it ethically difficult to justify further efficacy studies using placebo controls. However, 
extrapolation o f  the Ivory Coast trial to other regions within sub-Saharan Africa may not be jus­
tified because o f the relatively low bacterial resistance rates to CTX  in Ivory Coast. For exam­
ple, the resistance o f  NTS isolates to CTX  was only 14%. It has been suggested that these results 
should be investigated in regions with high bacterial CTX  resistance.20 In Malawi, the rate of 
resistance o f NTS and Streptococcus pneumoniae to CTX  is m uch higher (73 and 91% respec­
tively).6,21
The most optim al dosage o f CTX  still needs to be established in terms o f  efficacy, safety and 
cost. The W H O /U N A ID S recommends CTX  960 mg daily. In one study in the Netherlands
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cotrimoxazole in a dosage o f  480 mg had the same efficacy in preventing PCP as CTX  in a 
dosage o f 960 m g .22 In addition to reduced cost o f a single dose o f  480 m g ,23 side-effects may 
be less using C TX  480 mg in H IV  infected patients, in whom adverse effects to C TX  are known 
to be more frequent.24 Currently there are no data available on its use in African patients.
We decided to investigate the efficacy o f cotrimoxazole in preventing death and disease in H IV  
infected patients with active smear positive tuberculosis in Blantyre, Malawi. The original 
design was a randomised placebo-controlled trial. Soon after implementation o f the trial the 
results o f  the study in Ivory Coast became available.15 Ethical considerations, especially in light 
o f  a vigorous debate at that time about ethical aspects o f placebo-controlled studies in Africa25 
lead to our trial being terminated. The trial was then redesigned to compare two different 
dosages o f  cotrimoxazole (480 mg and 960 mg). We were interested in comparing case fatality 
rates, specific m orbidity and frequency o f  drug reactions during anti-TB treatm ent in patients 
who received the two different dosages o f  CTX. We also compared case fatality rates in patients 
on CTX  with those observed in a cohort o f HIV-positive new smear positive PTB patients 
recruited to a study in Zomba, Malawi in 1995 and with the reported case fatality rates in new 
smear-positive PTB patients registered in the National Tuberculosis Control Programme in 
1999.26,27 We were also interested to docum ent the operational problems encountered with the 
implementation o f this intervention in a health care setting in a developing country with high 
rates o f coinfection with tuberculosis and HIV.
Methods
The setting
The study was carried out at Queen Elizabeth Central Hospital (QECH) in Blantyre, Malawi 
from April 1998 until September 2001. Q E C H  is a large 1050-bedded teaching hospital and 
functions as a primary, secondary and tertiary facility. It is the only government hospital in 
Blantyre and health care is free o f  charge; the hospital serves the population o f the city as well 
as that o f  Blantyre district (estimated population o f 830 000 in mid-1998 [source — National 
Statistics Office]). Health care is provided free o f charge. The National Tuberculosis Control 
Programme (NTP) has an office at Q E C H  managed by a District Tuberculosis Officer (DTO).
Patients
In accordance with current guidelines o f  the NTP, patients suspected to have active pulmonary 
tuberculosis were requested to submit three samples o f sputum .28 These samples were examined 
for acid fast bacilli (AFB) in the hospital laboratory. Patients with a positive smear for AFB were 
referred to the D T O  for registration and treatm ent according to Malawi National TB
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Programme guidelines. Before starting treatment the study clinical officer screened the patients 
for inclusion in the trial. If  the patient was willing to participate he/she was counselled for H IV  
testing. Patients who fulfilled the following eligibility criteria were candidates for inclusion: 
patients older than 15 years, serological evidence o f H IV  infection, pulmonary tuberculosis 
diagnosed by sputum  microscopy reconfirmed in our research laboratory, resident and planning 
to stay in Blantyre district and surrounding areas for three years, and having given written or 
verbal informed consent. Patients were excluded on the basis o f the following criteria: a diag­
nosis o f active symptomatic bacterial infection other than tuberculosis or protozoal infection, 
known hypersensitivity to or intolerance to CTX, liver disease, as evidenced by clinically appar­
ent jaundice, inability to comply with protocol requirements, malignancy, inability to leave the 
bed unassisted to be weighed, being a prisoner, a vendor or a refugee, pregnancy or a previous 
episode o f tuberculosis.
Study methods
Each patient had a careful history and clinical examination. Blood and sputum  samples were 
taken. Eligible patients were randomised to receive either CTX  480 mg or 960 mg during TB 
treatment and to receive isoniazid or placebo after TB treatm ent whilst continuing with the 
assigned CTX  regimen. The latter part o f  the study aims to study the possible impact on 
secondary prophylaxis o f isoniazid on m ortality and relapse o f tuberculosis. The results o f this 
study will be reported separately.
Randomisation was done using a com puter generated randomisation list, using Microsoft Excel. 
An association o f two letters was randomly assigned according to this list to each consecutive 
patient in order o f enrolment. Each combination o f syllables corresponded to a simple dose of 
cotrimoxazole except for one o f them, which was a placebo. One group received once daily 480 
mg cotrimoxazole in the m orning (one active capsule o f  480 mg and one placebo capsule); the 
second group received once daily two capsules o f 480 mg cotrimoxazole in the m orning.
All study medication was identical in appearance and was manufactured by Genpharmaceutical, 
Johannesburg, South Africa. The enrolm ent o f the patients and the distribution o f  the capsules 
were done by the study clinical officers. Both the patients and the clinical officers (and all other 
members o f  the study group) were blinded to the treatment. Treatment for tuberculosis was then 
started with the standardised anti tuberculosis treatment regimen according to W H O  guide­
lines. This consisted o f one m onth o f daily streptomycin (intramuscular), and rifampin, 
isoniazid, and pyrazinamide (all oral), one m onth o f the same four drugs three times a week, 
followed by a continuation phase o f six m onths with daily isoniazid and ethambutol 
(IS H R Z /IS 3H 3R3Z 3/6 HE). All dosages were adjusted according to weight. During the two- 
m onth intensive phase the patients were adm itted in the tuberculosis wards.
The patients were followed up every four weeks at the research treatm ent clinic until the end of 
tuberculosis treatment. At each follow-up visit a brief history and clinical examination was
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obtained and CTX  was given for the next m onth. Samples o f blood and sputum  were taken 
according to protocol.
Patients were discontinued from follow-up after completion o f the study period, after death or 
near-terminal state, after voluntary withdrawal, or after moving out o f the district. Patients who 
did not show up for their scheduled visit or their relatives were visited at home by the study 
nurse and encouraged to resume attending the clinic. Patients were considered lost to follow-up 
if  they missed two consecutive visits. If  patients had died an attem pt was made to establish the 
cause o f death although our study originally was not designed to determine these causes. W hen 
a patient died the symptoms o f the last visit were correlated with the relatives’ description of 
symptoms at the time o f death when the death occurred at home.
Compliance was checked by a m onthly pill count at each visit. A patient was considered com­
pliant if  the ratio o f the total num ber o f  study drugs actually taken and prescribed was between 
0.6  and 1.0
W hen a serious adverse event related to cotrimoxazole occurred, the C TX  was stopped, but the 
patient was not withdrawn from the study.
Laboratory methods
At enrolment H IV  serology was performed using a H IV  rapid assay (HIV  Spot for HIV-1 and 
HIV-2, Genelabs diagnostics, Singapore). The samples that tested positive were confirmed by 
ELISA (Vironostatika, Organon, Boxtel, the Netherlands). A full blood count (FBC) with the 
measurement o f haemoglobin, haematocrit, platelets and white blood cell count with a differen­
tial count was done using a Coulter Onyx (Beckman Coulter, Johannesburg, South Africa). A 
count o f CD  4 positive T-lymphocytes was done using a FACScount (Becton Dickinson, Rivonia, 
South Africa) and later with a manual method (Coulter Onyx, Beckman, Johannesburg, South 
Africa). Aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) were measured 
by a kinetic m ethod (Human, Wiesbaden, Germany). Direct bilirubin levels were measured using 
a colorimetric test (Duomate DBIL, Human, Wiesbaden, Germany). Toxoplasma IgG levels were 
measured using ELISA (Clark Laboratories, Jamestown, NY, USA.
Sputum samples were stained with the Ziehl-Neelsen staining m ethod and microscopically 
examined for acid fast bacilli. A sample o f the sputum  was incubated for culture on a plate with 
Lowenstein-Jensen medium, which was produced locally. The plates were assessed for the 
growth o f  mycobacterial colonies every week until three months. Cases were defined as con­
firmed tuberculosis if  the culture grew mycobacterial colonies and as non-confirmed tuberculo­
sis if  the culture remained negative.
C D 4 count was repeated after two months, sputum  microscopy and culture were repeated after 
five and eight months, while FBC, ASAT, ALAT and bilirubin were repeated after two months 
and then after every three months until the end o f the study.
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Objectives
The primary objectives o f  this study were to assess i) the effect on survival o f the two dosages 
o f CTX  for primary preventive treatment in Malawi, with an added objective to compare the 
mortality rates o f  the study patients with those found in historical controls26 as well as patients 
registered in the N T P  in 1999 and ii) to assess the safety o f the two dosages o f C TX  in this set­
ting-
Secondary objectives were to assess i) the effect o f primary preventive treatm ent with the two 
dosages o f C TX  on the incidence o f bacterial pneum onia and other clinical events and ii) to 
assess the feasibility to deliver the two dosages in the investigated population.
Outcome
The primary efficacy outcome was death. The secondary efficacy outcome was an occurrence of 
a clinical event, defined as definite if  confirmed bacteriologically, as probable if  a patient had a 
clinical diagnosis o f the particular event responded to antibiotic treatment or as possible if  it did 
not respond to treatment. Safety was assessed by the occurrence o f adverse events, especially 
those that are known to be side effects associated with the use o f  CTX  (skin, bone marrow and 
gastric intolerance).
The Zomba cohort and patients registered in the Malawi NTP
The observational cohort o f  tuberculosis patients in whom  mortality was the main parameter 
recorded, has been previously described.26,27 We compared the outcome with patients who were 
HIV-seropositive and sputum-smear positive. We also compared outcomes with patients who 
had new smear-positive PTB registered throughout the country in 1999.
Statistical analysis
In the original study design a sample size o f 600 patients was calculated to detect a difference 
o f 2 0 % m ortality with 80% power and a two-sided significance o f  5%; this was left unchanged 
after the study was redesigned; to show equipotency between the two dosages the sample size 
would be 40,000 patients which is clearly unrealistic.
The analysis was conducted as an intention-to-treat analysis. Efficacy o f  the two dosages o f CTX 
was evaluated by comparing the two groups with respect to mortality, incidence o f events of 
pneum onia and other clinical events. The safety o f the two dosages was assessed by comparing 
the incidence o f adverse events. Furthermore, Kaplan Meier survival analysis was used with and 
w ithout stratification to age, C D 4 count and confirmation o f tuberculosis by culture. The pro-
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portional hazards model according to Cox was used to analyse the impact o f  several variables on 
the outcomes. An interim analysis was planned after the inclusion o f  300 patients to look at 
effect and attrition. The D ata and Safety M onitoring Board o f UNAIDS was asked to advise on 
progression o f  the trial after the interim  analysis. The comparison with the observational cohort 
in Zomba26,27 was done using Cox’ proportional hazards model. The comparison o f the case 
fatality rates with Zom ba and the N T P  were done using a X2 test. The study was approved by 
the National Health Science and Research Com mittee o f  Malawi and the UNAIDS Ethical 
Review Board.
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Results
Recruitment and follow-up
From March 1998 to January 2001 1795 patients were screened o f  whom 767 were enrolled in 
the trial. After enrolm ent another 188 patients turned out to be not eligible (figure 1). The 
remaining 579 were eligible for analysis. Two hundred seventy two patients received 480 mg 
C TX  and 307 patients received 960 mg CTX. The groups were comparable (table 1). At the 
end o f TB treatm ent 42 patients (7.2%) were lost to follow-up: 24 in the C TX  480 mg group 
and 20 in the 960 mg group. Furthermore, 74 patients were withdrawn from the study at the 
end o f TB treatment, because they missed two consecutive visits (22 patients), because they 
moved out o f the district (32  patients), and because o f the wish to withdraw from the study (20 
patients).
Death rates in the two groups
The number o f cases that died during the tuberculosis treatment until 30 September 2001 was 85. 
A t a cumulative follow-up period o f 332 person-years the mortality rate therefore was 25.6/100 
person-years. The case fatality rate at the end o f tuberculosis treatment was 14.7%. The relative 
risk of death was 1.14 (95% CI 0.74-1.74) for the CTX 480 mg group as compared to the 960 
mg group (mortality rate 27.4/100 person-years versus 24/100 person-years). The survival curves 
are shown in figure 2. There was a significant association o f older age with risk of death, whereas 
this could not be demonstrated for sex and CD 4 count (table 2). The established causes of death 
did not differ between the two groups (table 3).
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1795 Smear positive TB screened
1659 Accepted HIV rapid testing
136 Refused HIV testing
330 HIV negative
1329 HIV positive (100%)
795 Eligible according to inclusion /exclusion 
criteria (59.8%)
175 Was not resident of Blantyre or did 
not plan to stay in Blantyre during 
the next 3 years (13.2%)
256 Too sick, pregnant (19.3%)
23 Prisoner, vendor
Ineligible according to exclusion criteria:
n = 80 (6%)
0 History of severe reaction to isoniazid
9 History o f severe reaction to  cotrimoxazole
1 History of a serious life -  threatening 
opportunistic infection or malignancy
4 History o f jaundice or evidence of active liver 
disease
2 Expected inability to  comply with protocol 
requirements
1 History of tuberculosis
12 Deafness
2 Younger than 15 years old
17 Had TB treatment more than 8 days
6 Died before inclusion
15 Other
11 Unknown
----------------------------------------------------------------- ► 26 N ot willing to take study drugs
2 Did not come to inclusion visit
Figure 1 Screening profile. March 9th 1998 — January 26th, 2001
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Table 1 Demographical, clinical and biological characteristics o f randomized patients according to 
cotrimoxazole prophylaxis treatm ent arms
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Characteristics a t inclusion CTX 480m g arm CTX 960m g arm
N  = 272 N= 307
Age in year: mean (SD) 32,4 (30,4) 32,4 (30,8)
Age (year), % (n)
15-24 19,1 (52) 19,3 (59)
25-34 47,1 (128) 45,4 (139)
35-44 24,0 (66) 26,1 (80)
45+ 9,6 (26) 9,2 (28)
Male, % (n) 50,0 (136) 49,5 (152)
Body Mass Index in kg/m2: mean (SD) 17,6 (2,4) 17,3 (2,1)
< 16 (n) 22,8% (62) 24,4% (75)
16-17 (n) 16,5% (45) 17,9% (55)
17-18,5 (n) 26,1% (71) 25,7% (79)
18,5-25 (n) 26,1% (71) 24,4% (75)
> 25 (n) 1,8% (5) 0,3% (1)
Unknown (n) 6,6% (18) 7,2% (22)
CD4 count in cells/mm3: mean (SD) 238 (214) 221 (215)
0-99 (n) 25,7% (70) 28,7% (88)
100-199 (n) 27,2% (74) 28,0% (86)
200-349 (n) 20,2% (55) 19,9% (61)
>=350 (n) 21,7% (59) 17,3% (53)
Unknown (n) 5,1% (14) 6,2% (19)
Hemoglobin level in g/dl: mean (SD) 9.66 (2.00) 9.52 (1.95)
T b culture results in % (n)
M. tuberculosis 79,8 (217) 78,8 (242)
Culture negative 18,8 (51) 19,9 (61)
Unknown 1,5 (4) 1,3 (4)
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CTX960mg
CTX480mg
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Follow-up time (months) Log rank, p  -  0-5 6
Figure 2 Probability o f  survival during TB treatm ent according to treatm ent arms
Table 2 Incidence rate and rate ratio for m ortality during TB treatm ent period
M ortality Dead 
N  = 85
Alive 
N  = 494
H azard Ratio* 
(95% CI)
H azard Ratio 
adjusted*
(95% CI)
Age in years as % (n)
15-24
25-34
35-44
45+
7.1 (6)
47.1 (40)
27.1 (23) 
18.8 (16)
21.3 (105) 
46.0 (227) 
24.9 (123) 
7.7 (38)
ref
3.0 (1.27-7.09) 
3.18 (1.30-7.82) 
6.72 (2.63-17.2)
ref
2.74 (1.14.-6.61) 
2.69 (1.04-6.97) 
5.22 (1.88-14.54)
CD4 in cells/mm3 as % (n) 
0-199 
200-349 
> 350
66.7 (50) 
17.3 (13) 
16.0 (12)
56.9 (268)
21.9 (103) 
21.2 (100)
1.51 (0.80-2.83) 
1.03 (0.47-2.25) 
ref
1.38 (0.72-2.62) 
1.06 (0.48-2.35)
ref
Sex, as % (n)
Male
Female
51.8 (44) 
48.2 (41)
49.4 (244) 
50.6 (250)
ref
0.89 (0.58-1.36)
ref
1.11 (0.68-1.81)
* C ox  regression  M o d e l
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Table 3 Causes o f death during TB treatm ent according to C T X  prophylaxis arms
72
Causes o f death CTX 480mg CTX 960mg
Total number of death during TB treatment, % (n) 42 /272 43 / 307
Tuberculosis, % (n) 23.8 (10) 27.9 (12)
Gastrointestinal disease, % (n) 26.2 (11) 18.6 (8)
Pneumonia, % (n) 7.1 (3) 4.7 (2)
Meningitis, % (n) 7.1 (3) 18.6 (8)
Kaposi sarcoma, % (n) 2.4 (1) 0
Anemia, % (n) 2.4 (1) 0
Malaria, % (n) 2.4 (1) 0
Septicaemia, % (n) 2.4 (1) 0
Respiratory infection, % (n) 4.8 (2) 0
Other, % (n) 11.9 (5) 16.3 (7)
Unknown, % (n) 9.5 (4) 9.3 (4)
Table 4 Clinical outcomes during tuberculosis treatment according to cotrimoxazole prophylaxis arms
CTX 480m g 
arm
N  = 272
CTX 960mg 
arm
N  = 307
H azard Ratio* 
(95% CI)
H azard Ratio p-value 
adjusted**
(95%CI)
Patient with
at least one 127
clinical events
Bacterial 18
pneumonia
Incidence 12.3
(/100py)
Diarrhoea 
Incidence 
(/100py)
Malaria 
Incidence 
(/100py)
Meningiti 
Incidence 
(/100Ppy)
UTI/STD 
Incidence 
(/100py)
PCP
Incidence 
(/100py)
a 18
12.0
18
12.1
s 3
2.0
/  11
7.4
 2
1.3
Septicemia 12
Incidence 8.0
136
19
10.9
ref
28
16.2
ref
30
17.6
ref
6
3.4
ref
13
7.5
ref
2
1.1
ref
8
4.5
ref
1.07 (0.56-2.06) 1.08 (0.55-2.11) 0.83
0.62 (0.33 -  1.16) 0.64 (0.34-1.22) 0.18
0.69 (0.39-1.24) 0.71 (0.40-1.29) 0.26
0.58 (0.15-2.34) 0.59 (0.15-2.36) 0.45
0.99 (0.44-2.20) 1.34 (0.57-3.16) 0.51
0.59 (0.05-6.52) 0.47 (0.02-9.07) 0.62
1.76 (0.72 -4.31) 1.92 (0.77-4.74) 0.16
(/100py)
* C ox  regression  m o d el
** C ox  regression  m o d e l w ith  ad ju s tm e n t fo r  age / sex / b aseline C D 4  c o u n t/  Toxoplasma se ro logy/ b aseline T B  c o n firm a tio n / C T X  arm s
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Pneumonia and other clinical events
The observed num ber o f patients with one or more events o f pneum onia or other clinical events 
and the adjusted hazard ratios are shown in table 4. There were 62 events o f  bacterial pneum o­
nia in 37 patients, 8 o f  them were definite and 54 probable. Thirty  events in 18 patients 
occurred in the 480 mg group and 32 events in 19 patients occurred in the 960 mg group.
Figure 3 shows the Kaplan Meier curve o f remaining free from a bacterial pneumonia. 
Toxoplasma serology was negative in 90.0%, positive in 8.9% and indeterminate in 1.0%. We 
did no t diagnose a case o f Toxoplasma encephalitis.
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Figure 3 Probability o f  remaining free o f bacterial pneumonia during TB treatm ent according 
to treatm ent arms.
Table 5 Incidence rate and hazard ratio for mortality during TB treatm ent period for study groups and 
the Zomba observational cohort, 1995-1996
M ortality D eath Incidence 
(/100 py)
H azard Ratio
(95% CI)
H azard Ratio adjusted*
(95% CI)
P value
Patients with: 
No treatment 49 34.1 1 1
CTX 480mg 42 27.4 0.80 (0.54-1.22) 0.82 (0.54-1.24) 0.35
CTX 960mg 43 24.0 0.71 (0.47-1.08) 0.74 (0.49-1.12) 0.15
* A d ju s tm e n t o n  sex a n d  age
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Death rates compared to the Zomba cohort and the N TP
In our study groups the m ortality was lower compared to the observational cohort in Zomba 
although the hazard ratio did not show a significant level (table 5). The tuberculosis outcome 
parameters o f our study are summarised in table 6 and compared with the outcome parameters 
in the Zom ba cohort and the general outcome parameters o f the NTP. Case fatality rate o f the 
N T P  was significantly higher (p< 0.001) as compared to our study groups.
Table 6 Outcome parameters o f our study compared w ith the Zomba observational cohort and the N T P  for 
new smear positive PTB patients
CTX 480 mg(%) CTX 960 m g (%) N TP 1999 (%) Zom ba 1995 (%) 
1998-2001 1998-2001 n  = 8 185 n  = 255
n = 272 n  = 307
Cured or completed 62.9 58.6 71 69.4
treatment
Died 15.4 14.0 21* 18.0
Failed 3.7 3.9 1 1.2
Transferred 3 5.5
Defaulted*** 8.8 6.5 4 5.9
*p  < 0 ,0 0 1  as c o m p a re d  to  case fa ta lity  ra te  i n  C T X  4 8 0 /9 6 0  m g  (%2  test)
**p < 0 ,1 0  as co m p ared  to  case fa ta lity  ra te  in  C T X  4 8 0 /9 6 0  m g  (%2  test)
*** in  th e  s tu d y  g roups de fau lt are  th o se  p a tie n ts  w h o  w ere  lo s t to  fo llo w  u p  fo r  th e  s tudy
Adverse effects and compliance
The num ber o f adverse events are outlined in table 7. There were no significant differences 
between the two groups. Most events, which were thought to be related to CTX , were rash and 
gastrointestinal discomfort. 14.8% o f the side effects occurred in the first m onth. One patient 
in the CTX  960 group had to stop the prophylaxis indefinitely because o f the occurrence o f a 
Stevens-Johnson syndrome. The patient recovered from this event. The compliance o f the 
patients is shown in table 8 .
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Table 7  Comparison o f  adverse drug reaction during tuberculosis treatm ent according to cotrimoxazole 
prophylaxis treatm ent arms
CTX 480m g
Number (%)
CTX 960mg
Number (%)
Total number of patients 272
Patients with at least one clinical A DR 18 (6.6)
Total number of A DR 19 (7.0)
Evidence of CTX side effect 8 (2.9)
Gradel (mild) 8 (2.9)
Grade 2 (moderate) 0
Grade 3 (severe) 0
A DR during the first month 3 (1.1)
Study drug stopped because of adverse event 0
307
20
28 (9.1)
13 (4.2) 
10 (3.3)
1 (0.3)
2 (0.7)
4 (1.3) 
1 (0.3)
p-value
0.96
0.35
0.41
1.00
1.00
75
Table 8 Cotrimoxazole compliance according to C TX  prophylaxis treatm ent arms during TB treatment
CTX 480m g CTX 960m g p-value
N  = 272 N  = 307
Medication compliance*, % (n) 
Very low compliance 
Low compliance 
Normal compliance 
Over compliance
3.3 (8/244)
8.6 (21/244) 
73.0 (178/244) 
15.2 (37/244)
2.2 (6/268)
9.0 (24/268)
75.0 (201/268)
13.8 (37/268) 0.86
* C o m p lia n c e  ra tio  = n u m b e r  o f  em p ty  capsules /  n u m b e r  o f  theo re tica lly  p re sc rib ed  in  th e  p e r io d . V ery  lo w  co m pliance : ra tio  < 0 .6 ; low  
co m pliance : 0 .6  <  ra tio  < 0 .8 ; n o rm a l co m pliance : 0 .8  <  ra tio  <  1 .00; over co m pliance : ra tio  >  1.00.
Discussion
This study showed no significant differences in mortality and occurrence o f clinical events 
between 480 mg and 960 mg cotrimoxazole prophylaxis in H IV  positive smear-positive tuber­
culosis patients in Malawi. Furthermore, both dosages o f cotrimoxazole were well tolerated with 
equal compliance. In addition, the overall case fatality rate was reduced significantly as com­
pared to the case fatality rate in the National Tuberculosis Programme although not when com­
pared to the observational cohort in Zomba.
Tuberculosis, gastrointestinal disease and respiratory infection were the most commonly found 
causes o f death. M ost o f the deaths occurred within the first two m onths, which has been 
observed in the Zom ba cohort as well and could be a potential target for other interventions
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such as antiretroviral treatm ent.29 In line with other reports in Africa,26,30,31 m ortality was high­
er in older age groups suggesting advanced H IV  disease as a risk factor. However, this was not 
reflected in the CD 4 measurements as each C D 4 category carried equal risk o f death during 
treatm ent for tuberculosis.
W hen comparing with the overall countrywide case fatality rate o f  the N T P  for patients with 
smear positive tuberculosis, our study patients had a significant lower case fatality rate. This dif­
ference may in fact be more pronounced taking into account that in the N T P  data both HIV  
positive and negative patients are included; correcting for the lower m ortality rate in H IV  
negative patients (10% )26 and assuming that 72-80%  o f smear-positive patients are HIV  
positive, the N T P  m ortality figure for H IV  positive patients would be 23-25% . These data 
need to be interpreted with caution as patient characteristics in the various groups differ and 
our study patients were at the start o f the study not very ill and had the benefit o f being in a 
study.
There were no differences in clinical outcomes between the two study groups; bacterial pneu­
monia, diarrhoea, bacteraemia and malaria were most commonly found, whereas PCP was rare. 
Although this study was not designed to arrive at a firm diagnosis o f clinical events, these find­
ings are in keeping with data from other studies in Africa.6,8,21,32,33 It is likely that S. pneumo­
niae is among the commonest pathogens in patients with respiratory infection in our wards 
often becoming invasive;21 this was also found by others.8 No study is available on the cause of 
diarrhoea in Malawi; a recent study to the prevalence o f Cryptosporidium parvum  and Isospora 
belli found similar prevalence rates o f 11% and 2 .5%, for both pathogens, in patients with 
diarrhoea and w ithout diarrhoea, respectively (EE Zijlstra, unpublished observations). In con­
trast to what was found in Malawian children,34 PCP appears uncom m on in adults; similar low 
prevalence rates have been found by other studies in Africa3 except for the one report that 
published about a selected group o f patient in Zimbabwe.5,9,35
No case o f toxoplasmosis cerebri was diagnosed; it is possible that cases were missed as no C T  
scan was available and patients may have died in the ward or at home o f  rapidly fatal toxoplas­
mosis encephalitis. The seroprevalence o f anti-toxoplasmosis IgG antibody was however low 
(9.6%), suggesting a relatively low risk. The incidence o f Toxoplasma encephalitis (TE) in HIV  
infected patients directly correlates with the prevalence o f Toxoplasma gondii antibodies among 
the general HIV-infected population, the degree o f  im m une suppression, and the institution of 
prophylaxis against T E .36
C TX  may also have benefit through its well-recognised effect in treating Plasmodium falci­
parum, and CTX  preventive therapy may reduce the frequency o f episodes o f  malaria. Due to 
the absence o f a placebo-controlled arm this hypothesis remains speculation.
We are confident that the use o f  CTX  in H IV  infected patients with tuberculosis in this trial 
was safe. O nly one patient had a serious side effect, which led to withdrawal. This patient devel­
oped Stevens-Johnson syndrome from which she recovered. The other 36 events o f  side effects 
were mild and transient. This result confirms the reports from Ivory Coast,15 Senegal,17 and 
Thyolo District in Malawi.18 In the group o f patients who used 960 mg C TX  there were slight­
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ly more side effects than in the group who used 480 mg, but this was no t statistically signifi­
cant. There was a fair compliance o f CTX  use and a good tolerance o f the drug in combination 
w ith the antituberculous drugs. Most patients chose to continue the prophylaxis after the ter­
m ination o f the study. A considerable num ber o f  patients were lost to follow up or chose to 
withdraw from the study. The reasons for this withdrawal were mainly the burden o f too many 
drugs (TB treatment in addition with the two capsules o f CTX) and the alleged stigmatisation 
o f the study towards H IV  infection.
Although there are im portant methodological differences between studies, this study suggests 
that CTX  primary prophylaxis may have a potential beneficial effect on mortality in H IV  
infected smear positive TB patients and that low dose CTX  480 mg daily may be as effective as 
CTX  960 mg. The use o f  a single dose would reduce the costs by more than half. At the 
International Dispensary Association (IDA, Amsterdam, The Netherlands), which is the most 
frequently used supplier o f drugs in Africa a container o f 1000 capsules o f C TX  480 mg costs 
US$ 7.19 (0.72 cent per tablet), while 500 capsules with 960 mg cos t US$ 8.24 (1.65 cent per 
tablet), which means a cost reduction o f  56.4% .23
W hat can be learned from this study? Clearly, as other effective and affordable interventions are 
still beyond the horizon for the majority o f  patients, one would like to err on the side where 
patients who otherwise have a poor prognosis may benefit. In this context it is regrettable that 
randomised-controlled trials are still not available in southern Africa and that most studies that 
have been done have methodological problems. H igh levels o f  resistance to CTX  o f common 
bacteria such as S. pneumoniae and low prevalence o f other infections to which CTX  is targeted 
(PCP, toxoplasmosis, isosporiasis) should caution against overinterpretation o f the currently 
available data. In addition, implementation o f a strategy o f wide-spread use o f C TX  prophylaxis 
needs to be balanced against unwanted long term effects. The emergence o f antibiotic resistance 
to pathogens is a potential problem after widespread implementation o f CTX. In Malawi there 
is already a very high baseline resistance o f the most common pathogens against C TX .6,21 In a 
recent study there was an increase o f drug resistance to E. coli for CTX  in Thyolo district in 
Malawi after the implementation o f routine CTX  prophylaxis.37 The clinical consequences of 
this observation are not clear and needs to be investigated. O ther than in Ivory Coast a serious 
concern is the emergence o f cross resistance o f Plasmodium falciparum to a similar anti-folate 
combination, sulfadoxine-pyrimethamine (SP), which is now the first-line antimalarial drug in 
several o f  the African countries with the highest rates o f H IV  infection .20,38 As the only effec­
tive and affordable successor to SP, namely the combination o f lapudrine and dapson (Lapdap) 
that will be marketed soon is also an anti-folate this may have severe consequences for malaria 
control in the com munity as well as for treatm ent o f  the individual. Clearly these issues should 
be addressed urgently.
Taking all these considerations into account, a meeting was held in October 2002 between the 
College o f Medicine, the national TB programme, interested stakeholders and the Ministry of 
Health and Population o f Malawi to discuss these results as well as operational research data 
results from Lilongwe, Karonga and Thyolo. The outcome o f the meeting was a policy state-
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m ent which a) endorsed that Voluntary Counselling and Testing for H IV  (VCT) and CTX  pro­
phylaxis for H IV  seropositive TB patients be continued in those districts where it has been start­
ed, b) encouraged V CT plus CTX  prophylaxis for H IV  seropositive TB patients to be expand­
ed in other districts in a phased approach with results carefully monitored by the NTP, c) urged 
that the N T P  encourage and work with its partners to conduct a randomised controlled trial to 
determine the efficacy o f C TX  prophylaxis with and w ithout antiretroviral therapy in HIV  
seropositive TB patients and d) requested all parties to keep up to date with any new informa­
tion about the efficacy o f  CTX  prophylaxis in the region and act accordingly if  evidence sug­
gests that CTX  has harmful consequences.
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Summary
The article reports the results o f a study to determine the true outcome o f 8 months o f treat­
m ent received by smear-positive pulmonary tuberculosis (PTB) patients who had been regis­
tered as defaulters in the Queen Elizabeth Central Hospital (QECH) and Mlambe Mission 
Hospital (M M H ), Blantyre, Malawi. The treatm ent outcomes were docum ented from the 
tuberculosis registers o f  all patients registered between 1 October 1994 and 30 September 1995. 
The true treatment outcome for patients who had been registered as defaulters was determined 
by making personal inquiries at the treatment units and the residences o f patients or relatives 
and, in a few cases, by writing to the appropriate postal address. Interviews were carried out with 
patients who had defaulted and were still alive and with matched, fully compliant PTB patients 
who had successfully completed the treatm ent to determine the factors associated with default­
er status.
O f  the 1099 patients, 126 (11.5%) had been registered as defaulters, and the true treatment 
outcome was determined for 101 (80%) o f the latter; only 22 were true defaulters, 31 had com­
pleted the treatment, 31 had died during the treatment period, and 17 had left the area. A total 
o f  8 o f the 22  true defaulters were still alive and were compared with the compliant patients. 
Two significant characteristics were associated with the defaulters: they were unmarried; and 
they did not know the correct duration o f  antituberculosis treatment.
Many o f  the smear-positive tuberculosis patients who had been registered as defaulters in the 
Blantyre district were found to have different treatment outcomes, w ithout defaulting. The 
quality o f reporting in the health facilities m ust therefore be improved in order to exclude indi­
viduals who are not true defaulters.
Introduction
Malawi has had a National Tuberculosis Control Programme (NTP) since the country gained 
its independence in 1964 but, like many countries in sub-Saharan Africa, is now burdened with 
a large and growing tuberculosis (TB) problem, mainly as a result o f the epidemic caused by 
hum an immunodeficiency virus (HIV). In 1984, the TB programme adopted the DOTS 
(directly observed treatment, short course) strategy and was supported in this endeavour by the 
International Union against Tuberculosis and Lung Disease (IUATLD); all districts in the coun­
try implemented this strategy over the following 1-2 years. The good recording and reporting 
system, which is inherent in the DOTS strategy, allowed the TB epidemic to be reliably m oni­
tored, and the num ber o f notified cases rose from 5334 in 1985 to 20 630 in 1996 (Malawi 
NTP, 1996). As the N T P  struggled to cope with the increasing num ber o f cases and a deterio­
rating economic situation, national cure rates for smear-positive TB patients decreased from 
86 % in 1986 to 63% in 1992, and increased slightly to 6 8 % in 1994 (Malawi NTP).
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In Malawi, the TB registers are m aintained by the district TB officers (DTOs). Each registered 
TB patient is given a unique registration number, and the name, age, sex, address, date o f  diag­
nosis, type and category o f TB are recorded. Patients are treated with standardized antitubercu­
losis regimens, depending on the type and category o f TB. Newly diagnosed smear-positive pul­
monary tuberculosis (PTB) cases receive 8 months o f  short-course chemotherapy, comprising 2 
months o f  initial intensive treatm ent in hospital with daily supervised doses o f  streptomycin, 
rifampicin, isoniazid and pyrazinamide, followed by 6 months o f  unsupervised continuation 
therapy at home with isoniazid and thiacetazone or isoniazid and ethambutol. The drugs used 
in the continuation phase may be supplied to patients by the hospital or health centre. Sputum 
smears are examined after 2  months, 5 m onths and 8 months o f treatment, and the outcome at 
the end o f treatment is recorded according to the guidelines (see Table 1) established by the 
IUATLD and W H O .1,2
In the Blantyre district, which has 15 government health centres providing a TB service to the 
community, the cure rates in 1991 were less than 50%, with high default and transfer rates 
among patients.3 Although cure rates have improved since 1991, the recorded default rates are 
still unacceptably high at around 10±15%. Defaulters are an extra risk for the population 
because o f possible contagion and the development o f drug resistance by tubercle bacilli. The 
reasons for such defaulting in Malawi and other parts o f  sub-Saharan Africa are no t known, but 
may include failure to report or record the cure or death o f a patient, failure to collect the 
necessary drugs from the hospital or health centre because the patient was too ill, discontinua­
tion o f treatm ent by the patient after experiencing an initial improvement, and failure to noti­
fy the health care system that the patient had transferred to another health centre.
In the present study we investigated the status o f patients with smear-positive PTB who had 
been registered as defaulters in the two principal hospitals, which manage TB in the Blantyre 
district, and the possible reasons for their defaulting.
Patients and methods
The outcomes o f 8 months o f treatment o f all smear-positive PTB patients who were registered 
between 1 October 1994 and 30 September 1995 in the TB registers at the Queen Elizabeth 
Central Hospital and the Mlambe Mission Hospital, Blantyre district, were studied. The name, 
age, sex, home address and treatment unit o f patients who had been registered as defaulters were 
recorded, and a search was initiated to determine what had happened to them.
Between 31 December 1996 and 31 March 1997 the mortality records o f patients admitted to 
the hospital for the intensive phase o f treatment were inspected to determine whether those 
registered as defaulters had in fact died in hospital. The peripheral unit (usually a health centre) 
where the patients received the continuation phase o f treatment was then visited to determine 
whether there were any records o f the treatm ent outcome. If  there was no such record or the
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patient was still registered as a defaulter in the health centre, attempts were made to trace the 
patient or a relative in the home or workplace. This required making journeys to villages by 
motorcycle. If  there was still no trace o f the patient, a letter was written if  a post-office box num ­
ber was present in his/her treatment unit records or the TB register.
In this way we investigated and docum ented the true 8-m onth treatment outcome o f  patients 
who had been registered as defaulters. According to the IUATLD and W H O  definition ,1,2 true 
defaulters are patients who at any time during the course o f treatm ent had not collected their 
drugs for two or more consecutive months. All defaulting patients who were still alive, or a near 
relative, were interviewed (using a structured questionnaire) to determine the following: the cur­
rent health status o f the patient or, if  deceased, the date o f death; any financial or other diffi­
culties which prevented collection o f antituberculosis medication; the distance from the home 
to the health facility and the time taken to make this journey; and the presence o f any other 
disease besides PTB. In order to determine the factors that could have been associated with 
defaulter status, a second interview, using another questionnaire, was carried out with the true 
defaulters and with a group o f cured, fully compliant TB patients (matched for age and sex) who 
had been registered during the same period. This second interview, which was based on the 
health belief model,4-6 gathered information about demographic and socioeconomic variables, 
the patient’s health-seeking behaviour and knowledge about antituberculosis treatment, the 
continuing availability o f such treatment, the relations between the health care worker and the 
patient, the health status o f the patient during the continuation phase o f treatment, as well as 
ease o f access to the health unit.
Results
A total o f 1099 new smear-positive PTB patients were registered at the Queen Elizabeth Central 
Hospital and the Mlambe Mission Hospital during the 12-month study period; 126 (11.5%) 
o f  them had been registered as defaulters. Information about treatment outcomes was obtained 
for 101 (80%) o f  these defaulters (Table 1) through a home or village visit (100 cases) and by 
writing to one patient. Among patients whose treatm ent outcome was not a true default, we dis­
covered a failure in communication between the district TB officer and the health centre in 70% 
o f cases and between the patient and the health centre in the remainder.
Only 22 patients were true defaulters according to the IUATLD and W H O  definition .1,2 At the 
time o f the first interview, we found that 12 out o f the 22  true defaulters had died since the end 
o f  their 8-m onth treatm ent period, 1 patient had moved out o f  the area, 1 patient had been 
wrongly registered in another unit and had defaulted again from treatment, and 8 patients were 
alive and well. In our first interviews we investigated 20 cases (the 8 who were alive and the rel­
atives o f the 12 patients who had died). The most im portant findings from these interviews are 
shown in Table 2. We also compared the 8 defaulters who were still alive with a group o f age-
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and sex-matched cured patients who had been fully compliant w ith their treatment. The main 
differences between the two groups were as follows: all 8 compliant patients were married, com­
pared with none o f the defaulters; and 7 o f the compliant patients knew the correct duration of 
antituberculosis treatment, compared with none among the defaulters.
Table 1 True 8-m onth treatm ent outcomes for 101 study patients who had been registered as defaulters
True outcome No. of patients
Defaulted from treatment 22
(i.e. patients who during their treatment had not collected
drugs for two consecutive months)
Cured 27
(i.e. patients who had completed treatment and whose sputum smear
results were negative at the end of treatment)
Treatment completed 4
(i.e. patients who had completed treatment but whose sputum smear
results were not known at the end of treatment)
Died 31
(i.e. patients who had died during the 8-month treatment regimen)
Transferred 17
(i.e. patients who had transferred to another district and whose treatment
outcome was unknown)
Total 101
Table 2 Results o f interviews w ith 8 study patients and relatives o f  12 patients who had died,
concerning 20 defaulters
No. of defaulters 20
No. of males/females 14/6
Mean age (years) 38.9±13.0
Mean time to obtain the medicine (minutes) 147±118
Mean distance to hospital/health centre (km) 7.7±4.7
Mean survival time (months) 11.2±6. 5
Were there difficulties in obtaining medicine
in general?
Yes 89.5%
No 10.5%
Were financial problems incurred to obtain medicine?
Yes 55.6%
No 44.4%
Were there difficulties in obtaining medicine due to patients’ physical problems?
Yes 36.8%
No 63.2%
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Discussion
The true outcome o f 8 m onths o f treatm ent was determined for 80% o f the patients who had 
been registered as defaulters. The remaining 20% could not be traced because either their 
addresses in the TB register were incorrect and our inquiries in their villages did not help or our 
letters sent to their post-office box numbers were not answered. O f  the 101 patients who were 
traced, only 22 were true defaulters. The true default rate was therefore considerably lower than 
that given in the TB register. The possible causes for the different treatm ent outcomes and sug­
gestions for corrective measures are summarized in Table 3.
Table 3 Possible causes and treatm ent outcomes for 79 patients who had incorrectly been registered as 
defaulters, and possible corrective measures
Treatment outcome Possible causes Corrective measures
Cured or treatment
completed
(n= 31)
Transferred (n= 17)
Died ( n= 31)
a D T O :  d is tr ic t tubercu losis  officer
D TO  not visiting health 
centres a
Health centres not 
communicating with DTO
DTO s failing to communicate 
with each other
Difficulties in relatives 
providing information 
to health centres
Regular D TO  health visits to 
health centres a
Educate health centre staff 
about communicating the 
results o f treatment outcome
Quarterly D TO  meetings 
at regional level
Better follow-up by health 
centre staff would result 
from having adequate transport, 
staff numbers and training
About one-third o f the registered defaulters had in fact completed their treatment and many of 
them were cured. The D T O  was not aware o f this because either the officer had no t visited and 
checked the results in the treatment unit registers, or the patient’s transfer to another health cen­
tre had not been communicated to the D TO  (one-fifth o f the cases). Failure in communication 
between districts was also a problem, and this accounted for a small num ber o f defaulters who 
should have been registered as “transferred” to another health centre. About one-third o f the 
defaulting patients had died. Over 70%  o f tuberculosis patients registered for treatment at the 
Queen Elizabeth Central Hospital were HIV-seropositive;7 therefore, since the m ortality rates 
among HIV-infected TB patients in sub-Saharan Africa are high8-11 it is not surprising that 
many “defaulters’’ were in fact patients who had died. In the rural areas, w ith few telephones 
and difficulties in communication, it is unlikely that relatives would travel to the nearest health
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centre to report the death o f a patient when there is no incentive to do so. Health centre staff 
are supposed to follow up all defaulters, but owing to transport difficulties, increasing workload, 
lack o f motivation, concerns about safety in remote areas, and poor record-keeping, few o f them 
do so. Ways to improve communication between health facilities within a district and between 
different districts must therefore be found.
We investigated the reasons why patients defaulted. Although only a small num ber o f our 
defaulting patients could be compared with compliant cured patients, we found that unmarried 
status and ignorance o f the duration o f  antituberculosis treatment were characteristic of 
defaulting behaviour. The public should be given more information about tuberculosis, 
especially the total duration o f treatment and the need to complete the full course, via intensive 
health education through health care workers and the use o f posters, leaflets and flyers in the 
local language. Malawi is a poor country, and it is therefore unlikely that substantial socio­
economic and demographic improvements can be made in the near future.
This study may raise questions about the reliability o f data for other treatm ent outcomes. Cure 
rates and treatm ent completion rates can be verified from the patients’ treatm ent cards, and spu­
tum  smear results from the laboratory records. Details o f patients who move to another district 
should be recorded in the TB registers. These treatm ent outcomes are likely to be correct, 
although we have no t specially investigated this. Deaths cannot always be verified if  the patient 
died in the village, and further research to assess whether death rates are accurate is probably 
warranted.
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Impact of the human immunodeficiency virus on tuberculosis
The hum an immunodeficiency virus (HIV) has its greatest impact on tuberculosis (TB) in sub- 
saharan Africa, although in India and parts o f South -East Asia the association between these 
two infections is becoming increasingly apparent. H IV  has its impact in a num ber o f  ways, each 
o f which is a threat to good TB control.
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TB case numbers
In the last 10 - 15 years, TB case numbers have increased 300 - 400%  in high HIV-prevalent 
countries, mainly because H IV  increases the risk o f disease reactivation in people with latent M . 
tuberculosis and because H IV  infected persons are more susceptible to new TB infections. Along 
with the increase in case numbers there has been a disproportionate increase in cases with smear- 
negative pulmonary TB and extra-pulmonary TB. Increased case numbers throw an immense 
burden on TB control efforts: there is a need for more staff, particularly TB programme officers 
and laboratory personnel; there is a need for increased laboratory resources, drugs, sputum  con­
tainers, stationary; where patients are hospitalised for the initial phase o f  treatment, the wards 
become overcrowded rendering good nursing care impossible and increasing the risk o f noso­
comial infection; there is a need for more resources.
Increased morbidity and mortality
HIV-positive TB patients often run a stormy course while on anti-tuberculosis treatm ent with 
fevers, chest infections, recurrent diarrhoea, Candida and bacteraemia. Adverse reactions to anti­
tuberculosis drugs, particularly thiacetazone induced cutaneous reactions, are more frequent 
leading to interruptions o f treatm ent and occasional fatalities. It is not surprising that HIV- 
positive patients have a m uch higher mortality during and after anti-tuberculosis treatment 
compared with HIV-negative patients. In sub-Saharan Africa, approximately 30% o f HIV- 
positive smear-positive TB patients have died by 12 months o f  treatment, and about 25%  of 
those who survived will die during the next 12 months.
Recurrence o f TB after completing treatment
Recurrence rates (defined as return o f clinical evidence o f active TB, positive sputum  smears or 
positive cultures o f M . tuberculosis) are increased in HIV-positive patients. The use o f “standard 
treatm ent” and treatment interruptions due to drug reactions are associated with recurrence of 
TB. The proportion o f TB recurrence due to disease re-activation or re-infection is unknown.
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Drug resistance
Several outbreaks o f multi-drug resistant TB (M DR-TB) have been reported from industrialised 
countries amongst patients w ith HIV. H IV  does no t itself cause M DR-TB, but it fuels the 
spread o f this dangerous condition by increasing susceptibility to infection and accelerating the 
progression from infection to disease. Recent data collated from the W orld Health Organization 
(W H O ) has shown that M DR-TB is highest in India and South-East Asia and lowest in sub- 
saharan Africa. However, given the problems faced by many TB programmes in Africa and given 
the virtual absence o f second-line anti-tuberculosis drugs in these countries, M DR-TB is a real
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Tuberculosis Control: the W HO-DOTS Strategy
The overall objective o f  TB control is to reduce mortality, m orbidity and transmission o f the 
disease. A t present most TB experts believe that the best way to achieve this is to focus on new 
cases o f  smear-positive TB and to i) cure 85% o f detected new cases and ii) detect 70% o f exist­
ing cases. Achieving a high cure rate is the highest priority because TB programmes with high 
cure rates are thought to attract a large num ber o f existing cases in their catchment area. Giving 
priority to case finding before achieving a high cure rate increases the TB problem by creating 
M DR-TB. The strategy for TB control is the provision o f short-course chemotherapy (SCC) to, 
at least, all identified smear-positive TB cases (Table 1). There is insistence that any medication 
which includes rifampicin should be given by direct observation. The success o f  the TB control 
strategy depends on the implementation o f  a 5-point policy package (Table 2), the essential 
ingredients o f which were developed by Dr. Karel Styblo o f  the International Union against TB 
and Lung Disease (IUATLD) in the early 1980s.
Table 1 Short-Course Chemotherapy Regimens in W H O -D O T S Strategy
INITIAL PHASE (Daily or 3 times a week) C O N TIN U A TIO N  PHASE
2 EHRZ (SHRZ) 6 HE
2 EHRZ (SHRZ) 4 H R
2 EHRZ (SHRZ) 4 H 3R3
S = S trep to m y c in  E  = E th a m b u to l Z  = P y raz inam ide
R  = R ifam p ic in  H  = Ison iazid
T h e  n u m b e r  befo re  th e  f irs t le tte r  o f  each  p h a se  o f  th e  reg im en  is th e  D U R A T IO N  in  m o n th s  o f  th a t phase.
T h e  n u m b e r  i n  su b sc rip t a fte r th e  le tte rs  is th e  n u m b e r  o f  doses p e r  week.
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Table 2 TB Control Policy Package
1. Government commitment to a national TB control programme aiming at nationwide coverage.
2. Case detection through passive case finding.
3. Short course chemotherapy to, at least, all smear-positive TB cases.
4. Regular and uninterrupted supply o f essential anti-tuberculosis drugs.
5. A monitoring and evaluation system
There is evidence that the DOTS package works and works well. Cure rates are substantially 
higher in countries which have adopted the DOTS package compared with those using a non­
DOTS approach. Even in countries with high H IV  infection rates, such as South Africa, 
Tanzania and Malawi, good cure rates have been achieved.
The W HO-DOTS Strategy in the face o f HIV
Although DOTS is a successful strategy, its implementation is not easy. In 1995 the DOTS 
strategy was only being used nation-wide in 16% o f countries in the world. D O TS requires sus­
tained government com mitm ent, a strong national TB programme, a well functioning district 
health and laboratory service, free drugs and, above all, for resource-poor countries additional 
resources from the donor community.
H IV  adds its own set o f  problems to this scenario.
1 The targets for cure rates and detection rates are difficult to hit. Cure rates o f 85% in smear- 
positive TB cases are almost impossible to achieve because o f  high HIV-related mortality. The 
detection rate target o f 70%  is also impossible to achieve because a m ethod for estimating 
the total num ber o f  such cases has not yet been found.
2 H ot spots o f TB transmission, fuelled by concurrent H IV  infection, may occur in places 
where people are crowded together such as prisons, refugee camps, boarding schools and 
health care institutions. In such situations, active case finding may be a better strategy for 
case detection rather than passive case finding with its inherent delays and potential for fur­
ther TB transmission.
3 Thiacetazone, such a useful and cheap drug in the pre-HIV  era, has developed a bad reputa­
tion amongst health care workers and most segments o f the general population. Many TB 
programmes in Africa have abolished the drug, in favour o f ethambutol, leading to escala­
tion o f  drug costs and concerns about safety o f ethambutol usage in children. Even strepto­
mycin, because intramuscular usage may be associated with H IV  transmission and because 
it is difficult to administer out in the community, is being phased out in some TB pro­
grammes.
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4 Case holding in hospital TB wards, especially in urban areas, is becoming impossible because 
o f overcrowding, and moves are afoot to decentralise treatment to peripheral health centres 
and the community. This is a patient-friendly approach. However, the logistics o f observed 
drug administration, drug security (especially o f rifampicin), supervision, monitoring and 
recording in the com munity are daunting, although not impossible. Any scheme o f  decen­
tralization needs to be adapted to the local situation and carefully monitored in case there is 
loss o f control.
5 In HIV-positive, smear-positive TB patients the high death rates means that treatm ent is less 
cost-effective in terms o f years o f life saved than previously calculated for HIV-negative 
patients. In the pre-HIV  era, smear-negative PTB was a disease with a good treatment out­
come. Evidence is slowly accumulating in sub-Saharan Africa that HIV-positive smear- 
negative PTB patients have a worse prognosis compared with those who have smear-positive 
PTB. Yet these patients are ignored in the DOTS strategy despite the fact that their numbers 
are high. In many countries smear-negative TB cases are not routinely followed up, their 
treatment outcomes are no t reported and they are often given treatm ent inferior to that given 
to smear-positive TB cases.
6 It is a sad fact that health care staff in many African countries have the same HIV-sero- 
prevalence rates as the general adult population, and in some urban areas this approaches 
30% or more. High absentee rates due to illness or attending funerals, and high death rates 
due to AIDS threaten the infrastructure and efficient function o f the health services, and TB 
programmes are no exception. Manpower development needs to take this into account, and 
the concept o f one district TB co-ordinator for one district is no t enough.
Discussion
W idespread use o f isoniazid chemoprophylaxis has been put forward by some experts as an 
alternative approach to TB control in high HIV-prevalent areas. In controlled trials, isoniazid 
chemoprophylaxis appears to reduce the occurrence ofT B  in HIV-infected persons, but the fea­
sibility o f using this as a country-wide TB control measure is doubtful. A t present, the W H O - 
DO TS strategy has to be the best way o f controlling TB in high HIV-prevalent countries. 
Countries need to be helped in implementing this strategy with particular emphasis on quality 
microscopy-based diagnosis, health education, uninterrupted drug supplies and follow-up care. 
The D O TS strategy must also adapt to the challenges posed by the HIV  epidemic if  it is to 
maintain credibility in these areas. Ways o f  determining the TB case rate must be found, so that 
the 70%  detection rate target has some meaning. In certain circumstances, active case finding 
should be promoted. The issue o f smear-negative PTB must be addressed. C om m unity care 
schemes m ust be rigorously piloted and evaluated. Attempts m ust be made to reduce the high 
m ortality during treatment. There m ust be enough trained and motivated manpower to cope
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with the ravages o f the H IV  epidemic on the health care workforce. TB programmes should 
integrate more w ith AIDS control programmes, because it is becoming apparent that AIDS con­
trol is essential for TB control. Operational research, integrated within the national TB pro­
gramme structure, needs to be carried out under the direction o f  experienced personnel to try 
and provide answers to some o f these problems. Above all, governments and the donor com­
m unity need to be persuaded and reminded that good TB control is still very cost-effective, even 
with increased HIV-related mortality, and requires continued support.
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Chapter XA
Update on tuberculosis control in 
the face o f the H IV  epidemic 
in the era of highly active 
antiretroviral treatm ent
TB control and HAART
Introduction
In the last ten years the development o f highly active antiretroviral treatm ent (HAART) has 
accelerated. About 16 different drugs from three different classes have evolved from intensive 
research and more drugs are being developed every year. This has lead to a considerable reduc­
tion in mortality from H IV  infection.1,2 Globally, it is estimated that in 2002 from the 36 mil­
lion people living with HIV/AIDS about 6 million people are in need o f  HAART now. Instead, 
only 230 000 have access to HAART, and half o f them live in one country, Brazil, where the 
government offers HAART for free.
The average price o f HAART in industrialised countries was about e 10 000 - 12 000 per patient 
year. This meant that in Africa a wide implementation o f HAART was not considered to be real­
istic. Many efforts were made to put pressure on pharmaceutical companies to decrease the prices 
o f antiretroviral drugs. In 1997, in some o f the scientific journals the first cautious papers were 
published which speculated on introduction o f these drugs on a limited scale.3,4 These publica­
tions were the first o f a firm debate about the pros and contras o f this intervention.5-7
The debate
Arguments in favour o f the introduction o f HAART
— Inequity. There are strong moral and ethical pressures on the international com munity to 
resolve the appalling disparity between the treated and the untreated, between the rich and 
the poor. This has lead to the ‘great global alliance’, which U N  secretary general Kofi Annan 
has called for.
— Econom y. The H IV  pandemic is putting a heavy burden on the economies o f the countries 
involved, those economies that were already vulnerable and in a poor condition. H IV  takes 
away the economically strongest generation, those in the 2nd to 4th decade o f their live. The 
num ber o f orphans is growing beyond control. A major investment is needed to prevent the 
whole continent falling into an even lower abyss o f poverty and misery.
— Decrease o f  H IV  incidence. There is evidence that lowering the viral load with HAART 
may reduce the likelihood o f  transmitting H IV  to others up to 80% .8 Already established is 
the effect o f a reduction o f vertical m other-to-child transmission with antiretroviral treat­
m ent.9 Therefore, a serious attem pt to break the chain o f transmission can be made.
— Decrease o f  m ortality. The average life expectancy for an HIV-infected patient in the 
absence o f  treatment is approximately ten years.10 Rates o f progression appear similar by sex, 
race, and risk category, if  adjusted for the quality o f care.11 However and maybe therefore, 
this period is considerably shortened in Africa, which may be also because o f H IV  subtype 
diversity.12 HAART is expected to reduce HIV-related mortality considerably, as is already 
established in Europe.2
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Arguments against the introduction o f H AART13,14,15
— Less em phasis on  prevention. The introduction o f HAART will draw valuable funds from 
preventive measures, which are thought to be far more effective in preventing death and sav­
ing disability adjusted life years (DALY’s) than HAART.16 The ratio in cost-effectiveness of 
HAART and o f prevention is in some calculations 28:1.
— Cost. Two recent studies estimated the cost to m ount an effective and appropriate response 
to the H IV  pandemic to be about US $ 7.5 - 9.2 billion annually.7,17 This is an unprece­
dented am ount o f money, which has not been ever donated to health in the developing 
world. However, when seen in perspective, this is only 0.044%  o f the combined gross nation­
al product o f the 22 wealthy donor countries o f  the Development Assistance Committee of 
the Organisation for Economic Co-operation and Development (OECD). There is doubt 
whether these amounts o f money will be ever available. Furthermore, there could be a per­
ception that HAART will draw effectively more attention and therefore leverage funds to the 
whole H IV  problem. According to critics, this leverage effect has to be very large to be cost 
effective.13
— T he danger o f  a fu rthe r collapse o f  the health  infrastructure. If  HAART was to be imple­
mented, the danger exists that money will be invested in the HAART programme, which was 
earmarked for other health purposes. This can potentially backfire leading to a further 
destruction o f already fragile health systems that are in some countries at the threshold of 
total collapse.
— Transm ission m ay n o t be inh ib ited . A large portion o f H IV  transmission occurs before the 
appearance o f symptoms, and therefore before the initiation o f  therapy.18 Furthermore, 
patients on HAART live longer; therefore they are potentially able to transm it the virus for 
a longer period. This effect will be stronger when treatm ent compliance is not assured. The 
dynamics o f  H IV  transmission and its epidemiology needs to be established further.
— T he danger o f  increase o f  unsafe sexual behaviour. A recent study has shown that 
H IV  prevalence in Brazil has risen since the implementation o f  free HAART. This effect is 
attributed to a decrease o f  condom use and an increase in unsafe sex practices.19,20
— T he danger o f  th e  em ergence o f  viral resistance: W hen treatment compliance is less than 
90%, there is an increased risk o f the emergence o f  viral resistance. This may lead to a re­
emergence o f  H IV  infection after an initial decrease.14
The status quo o f HAART in Africa in 2003
Among all interventions in H IV  control, w ithout doubt the greatest improvement in quality of 
live and the largest reduction in mortality in H IV  infected individuals will be achieved with 
HAART. The major problems o f a widespread use o f HAART are caused by the costs, the drug 
delivery and the assurance o f compliance.
In April 2001, in anticipation o f the United Nations General Assembly Special Session on
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HIV/AIDS (UNGASS) that was to be held in New York in June 2001, a new institution o f the 
W H O  was established: the Global Fund to fight AIDS, Tuberculosis and Malaria. This body 
has received pledges totalling US$ 2 billion o f new funding and estimated that 7.5 billion 
US$ per year is needed to meet its targets. Now, with more money possibly available from 
several institutions such as the Bill Gates Foundation, the Clinical Trial Platform for tuberculo­
sis, malaria and HIV/AIDS (an initiative o f the European Union) and others, this may be part­
ly feasible.
W H O  recently have proposed guidelines for the scaling up o f antiretroviral drugs in resource- 
limited settings.21 They recommend starting HAART in adult and adolescent HIV-1-infected 
patients with a CD 4 count o f less than 200 cells/pl and/or in W H O  stage 4 (in general the stage 
with the occurrence o f opportunistic infections).22 These first guidelines provide a framework 
for the national AIDS control programmes in resource-limited settings for the delivery and 
monitoring o f various HAART regimens and the supporting network. O f  course, many research 
questions remain to be answered:23 is there a clinical advantage to start HAART in patients with 
a CD 4 count > 200 cells/pl, and are there other (and cheaper) laboratory or clinical markers 
that can successfully guide decisions about when to start HAART.
The framework, in which HAART will be delivered, is essential for an introduction o f HAART 
in Africa to avoid problems that cannot be solved. The minimal conditions, necessary to make 
this introduction feasible, are that the drugs must become more affordable and that more, and 
sustainable funds must become available. Secondly, a system for continuous drug delivery, and 
the assurance o f the quality o f drugs, must be construed. Finally, a key question will be how to 
assure the follow-up and monitoring o f treatment compliance and adverse events, equivalent to 
D O TS in TB programmes.
The role o f HAART in TB control
HAART has probably a major impact on TB transmission. Some authors are o f the opinion that 
TB control w ithout H IV  control is impossible.6 I have described the negative effects o f  the HIV  
epidemic on TB control programmes in Chapter X. One o f  the specific problems that face the 
HIV/AIDS control programmes is the relative lack o f  success o f the Voluntary Counselling and 
H IV  Testing Centres (V C T’s). Nearly 90% o f infected people in Africa do not know their HIV  
serostatus.24 Generally this is thought to be due to a shortage o f accessible V C T ’s, poor quality 
and logistics and a denial o f  AIDS by individuals, communities and even governments. 
However, a potential boost in the efficacy o f the V C T ’s could be the link o f  the counselling and 
testing with provision o f care. This care can consist o f standard care, the treatment o f S T D ’s, or 
the availability o f prophylaxis with cotrimoxazole and/or isoniazid. W ithout doubt, the most 
powerful incentive for patient to have their H IV  serostatus determined would be antiretroviral 
treatm ent because o f its ‘curative’ element.
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HAART will lower the transmission o f HIV. For the same reason one can contemplate a 
decrease o f incidence o f TB. This will be due to a decreased num ber o f  latently infected patients 
who will develop secondary reactivation PTB, a decreased num ber o f contagious patients and 
finally less patient-to-patient transmission and therefore fewer newly infected patients who are 
additionally less susceptible for these new infections when HIV  seronegative. Moreover, the 
num ber o f  relapses o f TB is also expected to decrease. The first evidence to confirm this theo­
retical model has already been established. In a study o f 264 HIV  infected TB patients in South 
Africa a reduction o f 80% in m ortality was achieved. According to this study a prevention of 
14-20 cases o f  TB per 100 patient-years o f treatment in this patient category would be 
achieved.25
In general, there have been few clinical studies that investigate the simultaneous treatment of 
H IV  and TB. There are some practical and logistical difficulties to consider with the introduc­
tion o f HAART in TB patients.
1 Pharmacological difficulties. There are serious interactions between antiretroviral drugs and 
rifampicin. More specifically, treatment with protease inhibitors and rifampicin at the same 
time is pharmacologically complicated and therefore discouraged. The simultaneous thera­
py o f non-nucleoside reverse transcriptase inhibitors (N N R TI’s) and rifampicin is feasible, 
but needs an adjustment o f dosages. The exact interactions and adverse effects o f  this com­
bination need to be studied more carefully. Probably, the only combination with no relevant 
interactions is between nucleoside reverse transcriptase inhibitors (N R TI’s) and the antitu- 
berculous drugs.26
Starting both treatments (seven different drugs) at exactly the same time is another concern. 
W hen an adverse event occurs, it will be difficult to assess which drug causes this event. 
Therefore, it is advised to wait a m inim um  period of, e.g. 2 months with HAART after 
tuberculosis treatment has begun.
Another aspect o f this approach is the m atter o f early mortality. There is a high m ortality in 
HIV-seropositive PTB patients, w ith approximately one third o f  the m ortality occurring in 
the first months o f  the TB treatment. A way o f trying to lower this early mortality could be 
to start HAART in the first days o f TB treatment. An interesting subject o f research is to 
observe the problems that can be encountered in this early simultaneous treatment.
2  Logistical difficulties-, how to use the TB infrastructure for HAART drug delivery.
a) Most o f the African N T P ’s have a long experience in the delivering and monitoring o f TB 
therapy. This infrastructure could be well used for the administration o f HAART in gener­
al or o f HAART restricted to TB patients. Adverse effects o f  both treatments are best m an­
aged in a single programme. A possible disadvantage o f such a jo in t approach would be the 
overburden o f the N T P ’s. Therefore, these programmes need to be provided with sufficient 
funding, manpower and training to deal w ith this enormous task. Furthermore, if  the N T P 
allocations are used for HAART delivery in general one should be aware o f  the risk o f H IV  
positive patients w ithout TB acquiring TB when undergoing HAART if  they had to join the 
outpatient queues with a mixed population.
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b) Another possible solution o f drug delivery could be provided by the existing structure of 
V C T ’s. In these centres the counselling and H IV  testing, the treatm ent o f S T D ’s, the pro­
vision o f prophylaxis, the delivery and monitoring o f TB drugs and the delivery and m oni­
toring o f HAART could be offered as a package. Again this will need an enormous effort in 
strengthening the capacity o f these V C T ’s in terms o f hum an resources, funding and organ­
isation.
c) There is a risk o f emergence o f  resistance o f  H IV  when treatm ent compliance o f HAART 
is insufficient.14 Therefore, a similar system o f observed treatm ent is suggested as in D O TS.5 
An additional argument is the expected street value o f HAART drugs. Closed observation 
to prevent HAART drugs being traded at street markets is necessary. Moreover, the lifelong 
provision o f HAART will be a major logistical problem.
3  When to start: Another question to be answered is the mom ent when to start with HAART.23 
W H O  recommends that patients with the dual infection o f  TB and H IV  complete their TB 
therapy prior to HAART, unless there is a high risk o f H IV  progression and death during 
that period o f TB treatment. The current W H O  guidelines recommend starting HAART 
when the C D 4 count is below 200 cells/mm.3,21 However, TB patients co-infected with 
H IV  have a high early mortality.27 An im portant research question is to investigate whether 
it is possible and clinically feasible to start HAART and TB treatment at the same time.
In my view, a wide-scale introduction o f antiretroviral treatment in Africa will be hard to stop. 
From an ethical and philosophical perspective, withholding a potentially life-saving treatment 
in one part o f  the world, while widely available in other parts, is no t easy to defend, even if 
cost effectiveness theories show that the balance points towards prevention only. Until a more 
definitive solution such as a vaccine is found all efforts should be mobilised to fight this cata­
strophe, both AIDS and tuberculosis, in all possible ways. All possible measures, such as pre­
vention, prophylaxis, and antiretroviral therapy should be fully exploited. To prevent anarchy 
and the consecutive emergence o f viral resistance, research m ust be directed towards determin­
ing when to start treatment, how to m onitor the treatment, which drugs are the best combina­
tion, and how to assure adherence to treatment. Furthermore, this research m ust provide 
answers about adequate logistics and funds in a cost effective manner. A simultaneous em pha­
sis on the improvement o f prevention o f H IV  transmission through behavioural change will be 
a continuing challenge.
Inevitably, the fight against AIDS is essential in TB control. W hile continuing the present clas­
sical TB control measures, the battle against the dual epidemic cannot be won w ithout the full 
employment o f  all AIDS control measures including HAART.
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Summary
This thesis describes some studies and reflections on aspects o f  tuberculosis control in Africa, 
specifically in Malawi, in the face o f the HIV  epidemic. In the research agenda o f the National 
Tuberculosis Control Programme (NTP) in collaboration with the College o f Medicine o f the 
University o f Malawi several topics have been identified for operational research to improve 
control measures in the fight against TB and AIDS. Some o f these various issues and the 
studies, which resulted from it, form the basis o f this thesis.
In C hapter I, a general introduction is given and an outline o f the thesis. The problem o f TB 
and H IV  is pu t in epidemiological perspective, globally and in Africa. Some information about 
Malawi is discussed, especially its political and health situation. An inventory is made o f the 
constraints o f the NTP, and the implications that this has for an operational research agenda. 
In C hapter II, a study is presented o f  the size o f a possible gender difference in TB control. 
W omen in low-income countries are probably undernotified compared to men. In this study we 
were interested to assess whether there is a sex difference in numbers o f sputum  submission and 
numbers o f suspects with positive sputum  smears in Malawi. We examined the laboratory 
registers in all diagnostic units in eight (rural, semi-rural and urban) districts for the years 1995 
and 1996. We found that during a 12-month period o f  about 27 000 new TB suspects 52% 
males and 48%  females submitted sputum  samples. O f  approximately 3 000 smear-positive 
sputum  samples 53% were from male and 47%  from female patients. Both differences were sta­
tistically significant, and these differences were m aintained after correction for gender distribu­
tion in the general population. These results supported the suggestion that gender differences 
are im portant in control programmes and may reflect differences in access to health care.
In C hapter III, a strategy is tested for the diagnosis o f tuberculous lymphadenitis in the low 
resource conditions o f  health care as seen in sub-Saharan Africa and with the background of 
a high H IV  co-infection rate. In a prospective study the results o f  four basic procedures 
diagnosing tuberculous lymphadenitis w ith the outcome o f  histology and/or culture are com­
pared. These four procedures were: a wide needle aspiration looking at i) macroscopic caseation 
and ii) the Ziehl-Neelsen (ZN) stain and a lymph node biopsy again looking at iii) macroscopic 
caseation and iv) the Z N  stain. There were 52 outpatients with extra-inguinal lymphadenopa- 
thy in whom all procedures were carried out. O f these, 73%  were diagnosed as tuberculous lym­
phadenitis; 84% o f the latter were seropositive for HIV. Needle aspirate and biopsy smears 
stained by the Z N  technique contributed little to detecting tuberculosis, 8% and 11% respec­
tively. In contrast, macroscopic caseation o f  excised lymph nodes showed a high yield o f 82%, 
which was similar to histology, and higher than that o f culture (61%). Results showed that HIV- 
positive patients with TB lymphadenitis had a reduced frequency o f  histology and culture being 
positive for tuberculosis. Histology results, often used as the single definitive method, failed to 
diagnose 18% o f tuberculosis cases. However, it was reassuring that four simple methods, which 
can safely be carried out at district level, could be expected to diagnose 80-95%  o f tuberculous 
lymphadenitis cases in a timely and cost-effective manner.
In Chapter IV, a study was carried out on the role o f traditional healers and traditional medicine
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for patients with TB in Malawi. This was assessed by a questionnaire study on 89 smear-positive 
pulmonary TB patients admitted to Queen Elizabeth Central Hospital (QECH) in Blantyre, 
Malawi. Furthermore, seven traditional healers were also interviewed about their knowledge, atti­
tudes and practice o f patients whom they considered to have TB. O f these 80 patients, 37% 
admitted to have visited a traditional healer before seeking regular medical care. Patients spent a 
median length o f 4 weeks with the traditional healer. During this time, 72% did not improve or 
deteriorated while on traditional treatment. No patient was referred to the medical services by the 
traditional healer. All traditional healers claimed to know about TB. Four patients said they would 
refer a patient to hospital if  their treatment were not curative. Six traditional healers claimed to 
have cured 116 patients with TB in one year. We concluded that it is important to involve tradi­
tional healers in the educational activities o f the NTP. These healers need to be taught to recog­
nise and refer patients with TB, whom they should not treat, but at the same time be encouraged 
to administer safe treatments for conditions that are more amenable to their practice. This study 
was important in being the first study in Malawi to assess the role o f traditional healers in causing 
diagnostic delays for patients with PTB. As a consequence, the Malawi N T P engaged in other 
studies to investigate traditional healer beliefs and invested in training o f traditional healers in all 
districts around the country. Between 1998 and 2000, just under 6 000 traditional healers were 
trained about the importance o f TB and about the need to refer patients with cough to hospital 
for further investigation. In its 5-year development plan (2002-2006), the N T P has a budget line 
o f US$ 20 000 per annum for traditional healer training
The results o f the study in Chapter 4 contributed to the design o f the study described in 
C hapter V. We did structured questionnaires completed by interviews in about 1 000 patients 
registered with PTB in government hospitals in five districts in Malawi. These questionnaires 
were to determine aspects o f care seeking behaviour and diagnostic processes in smear positive 
PTB patients. The median delay between onset o f cough and diagnosis was 8 weeks. There was 
a variable pattern o f  care seeking behaviour, w ith 70% o f patients initially visiting a place of 
orthodox medical care and 30% visiting traditional healers, grocery shops, etc. O f  these, 79% 
o f the patients had one or more subsequent contacts for help, w ith these visits targeted more to 
orthodox medical care. A t all stages, antibiotics resulted in symptomatic improvement in up to 
40%  o f cases. There was a median time o f 7 weeks between cough and first submission o f spu­
tum  specimens. Almost all patients received sputum  smear results after a median length o f 4 
days. 43% o f patients were only aware o f their diagnosis at the time o f  receiving smear results, 
this observation being significantly associated with lack o f schooling and not knowing another 
person w ith TB. We concluded on the basis o f  these findings that more needs to be done to edu­
cate communities and non-orthodox care providers about the diagnosis and treatm ent o f TB. 
In C hapter VI, a laboratory study was performed to determine how long sputum specimens from 
smear-positive tuberculosis patients can be stored at room temperature or in the refrigerator and 
retain a positive acid-fast bacilli (AFB) smear or a positive mycobacterial culture. This was impor­
tant because in remote health centres where facilities are not always available to stain and examine 
samples, specimens need to be stored and examined in a later stage to diagnose TB. Furthermore,
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some samples are submitted for culture and assessment o f drug sensitivity to the Central Reference 
Laboratory in Lilongwe. These samples need to be stored and transported.
Sputum samples from 30 patients were examined up to 4 weeks and samples from 13 patients 
examined up to 8 weeks. If provided samples had not dried out, all sputum smears remained AFB 
positive up to 4 and 8 weeks. In both patient groups, at 4 weeks 37-39% o f specimens at room 
temperature grew Mycobacteria compared with 54-67% o f specimens stored in the refrigerator. 
These results have implications for tuberculosis programme policy. Laboratory technicians should 
not discard specimen which arrive late from health centres and specimen should be and can be 
stored in the refrigerator before transportation to a central laboratory for culture even after 4 
weeks.
In C hap ter V II and V III an im portant issue o f TB control in the H IV  positive population was 
studied and discussed. The m ortality in HIV  infected TB patients is very high as compared to 
H IV  negative TB patients. Routine antiretroviral treatment is not available at the present time 
and sub-Saharan Africa is desperately seeking for other cost effective measures to decrease the 
time to fatale outcome.
Prophylactic treatm ent w ith cotrimoxazole (CTX) has shown to be effective in reducing m or­
tality in this patient category. We conducted a randomised, double-blind study to compare the 
efficacy and safety o f  two different dosages o f C TX  (480mg and 960 mg) in preventing m or­
tality and morbidity, particularly bacterial pneumonia. Furthermore, we compared the outcome 
o f  our patients with an unselected cohort o f TB patients registered in Zomba, Malawi in 1995 
and with the treatment outcomes o f the N T P  in the same period the study was conducted. We 
found that there were no statistical significant differences in m ortality and occurrence o f bacte­
rial pneum onia in the groups receiving the two different doses. The case fatality rate at the end 
o f  the PTB treatm ent (8 months) was 15.4% in the CTX  480 mg group and 14.0% in the CTX 
960 mg group. This was lower than the case fatality rate in the Zom ba cohort (19.2%) and sig­
nificantly lower than the case fatality rate o f the N T P (21.0%). CTX was well tolerated, and only 
one patient had to stop prophylaxis because o f a serious side effect. We felt that the study pro­
vided circumstantial evidence that cotrimoxazole prophylaxis has a beneficial effect on m ortal­
ity and m orbidity in H IV  infected smear positive PTB patients. Furthermore, the efficacy o f a 
dosage o f 480 mg CTX  is not significant different from a dosage o f 960 mg. Both doses o f  cot- 
rimoxazole are well tolerated, and the intervention is cheap and easy to implement. In conclu­
sion, after taking all the considerations into account a meeting was held in October 2002 were 
a statement was made that i) C TX  prophylaxis for H IV  seropositive TB patients be continued 
in those districts where it has been started, ii) CTX  prophylaxis should be encouraged to be 
expanded in other districts in a phased approach with results carefully m onitored by the NTP, 
iii) a randomised controlled trial to determine the efficacy o f CTX  prophylaxis w ith and with­
out antiretroviral therapy in H IV  seropositive TB patients should be encouraged and finally iv) 
the N T P  should keep up to date with any new information about the efficacy o f  CTX  prophy­
laxis in the region and act accordingly.
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In C hapter IX, the problem of treatment compliance within the N T P is addressed. The average 
default rate in the N T P  in smear positive PTB in the last ten years was about 11%. We were 
interested in the true outcome o f 8 m onths o f treatm ent received by smear-positive pulmonary 
tuberculosis patients who had been registered as defaulters in the Q E C H  and Mlambe Mission 
Hospital (M M H). In addition, we were interested in possible reasons for default in these 
patients. The true treatm ent outcome o f 101 patients in 1995 who had been registered as 
defaulters was determined by making personal inquiries at the treatm ent units and the resi­
dences o f patients or relatives and, in a few cases, by writing to the appropriate postal address. 
Interviews were carried out with patients who had defaulted and were still alive and with 
matched, fully compliant PTB patients who had successfully completed the treatm ent to deter­
mine the factors associated with defaulter status. O f  these 101 patients only 22 were true 
defaulters, 31 had completed the treatment, 31 had died during the treatment period, and 17 
had left the area. A total o f  8 o f  the 22 true defaulters were still alive and were compared with 
the compliant patients. Two significant characteristics were associated with the defaulters; they 
were unmarried; and they did not know the correct duration o f antituberculous treatment. We 
concluded that many o f the smear-positive tuberculosis patients who had been registered as 
defaulters actually did no t default and were found to have different treatm ent outcomes. We 
learned from this study that the quality o f reporting in the health facilities had to be improved 
in order to exclude individuals who are not true defaulters, and that patients m ust be informed 
about the duration o f anti-TB treatment..
In the last chapters, C hapter X  and Xa, a covering opinion paper was written about the possi­
ble strategies o f TB control in the face o f the H IV  epidemic in sub-Saharan Africa. The first sec­
tion was written and published in Tropical Doctor in 1998. An update o f  this strategy is given 
in 2003 with the background o f the developments in antiretroviral treatment and the advance­
ments in drug delivery programs.
The problems o f TB control in the era o f H IV  infection are outlined: increased numbers o f  TB 
cases, increased morbidity and mortality, increased recurrence o f TB after treatment, and the 
possibility o f the emergence o f drug resistant TB. The contemporary DO TS strategy o f the 
W H O  is explained and critically reviewed in the face o f these increasing problems. The targets 
for cure rates (85%) and detection rates (70%) are difficult to hit because o f high HIV-related 
mortality and because a m ethod for estimating the total num ber o f cases o f TB has not yet been 
found. An argument is made for active case finding in some spots such as prisons and hospitals. 
The disappearing o f some cheap and readily available drugs such as thiacetazone and in some 
respect streptomycine is mentioned. The problems o f case holding in hospitals and the resulting 
overcrowding o f  the wards are discussed with possible solutions o f  ambulatory treatment. The 
devastating high mortality in smear negative PTB is a demoralizing development that is not tar­
geted in the D O T  strategy. Finally, the impact o f the epidemic on the health staff itself and the 
quality o f the N T P  infrastructure is an additional concern.
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In the discussion some options for approach are mentioned: 1) the use o f  isoniazid chemopro­
phylaxis 2) the creation o f the best conditions (financially, logistically, and operationally) for 
the W H O -D O T S  strategy 3) finding ways o f determining the TB case rate 4) prom otion of 
active case finding in some circumstances 5) addressing the issue o f smear-negative PTB 6) the 
rigorously piloting and evaluating o f  com munity care schemes 7) an attem pt to reduce the high 
mortality during treatm ent e.g. by cotrimoxazole prophylaxis 8) ensure enough trained and 
motivated manpower in the health care workforce 9) integration with AIDS control pro­
grammes.
In a 2003 update an overview is given o f the intentions to implement Highly Active Anti 
Retroviral Treatment (HAART) in the treatm ent o f  TB patients. The arguments in favour and 
against that are used in the debate whether to introduce HAART on a wide scale in Africa are 
discussed. The current progression o f  HAART programmes in general and more specifically in 
connection with TB programmes is outlined. Furthermore, the pharmacological and logistical 
problems o f the concurrent use o f  TB treatment and HAART are discussed. Finally, the chap­
ter ends with a personal view o f the way forward in tuberculosis control in Africa in the face of 
the H IV  epidemic in the era o f highly active antiretroviral treatment.
Samenvatting
D it proefschrift beschrijft enkele studies van en bespiegelingen over aspecten van tuberculose 
(TB) controle in Afrika, speciaal in Malawi, in het tijdperk van de pandemie met het humane 
immunodeficiëntie virus (HIV). O ok in Malawi veroorzaakt deze co-infectie grote problemen. 
H et Nationale Tuberculose Controle Programma (NTP) van Malawi in samenwerking met de 
Faculteit Geneeskunde van de Universiteit van Malawi legden daarom in 1995 de fundamenten 
van een strategisch plan van aanpak in een poging om de gevolgen van deze problemen te con­
troleren. D it plan leidde to t een research agenda m et verschillende onderwerpen voor operatio­
neel onderzoek om de controle maatregelen in het gevecht tegen TB and AIDS te verbeteren. 
Sommige van deze onderwerpen en de studies die eruit volgden, vormen de basis van dit proef­
schrift.
In hoofdstuk  I wordt een algemene introductie gegeven en een overzicht van de achtergronden 
van het proefschrift. De epidemiologie van TB en H IV  wordt beschreven, zowel globaal als in 
Afrika. H et hoofdstuk gaat in op sommige aspecten, die van belang zijn voor Malawi, m et name 
de politiek en de gezondheidszorg. Vervolgens worden de problemen van het N T P  geïnventari­
seerd, van waaruit een operationele research agenda kon worden gemaakt.
In hoofdstuk  II wordt het onderzoek beschreven naar de omvang van een mogelijk man/vrouw 
verschil in het diagnostische proces naar open TB in Malawi. Bij vrouwen m et TB uit landen 
met lage inkomens wordt waarschijnlijk m inder vaak de ziekte daadwerkelijk vastgesteld en dus 
geregistreerd dan bij mannen. We keken in deze studie vooral naar het man/vrouw-verschil in 
het aantal monsters ingeleverd sputum  en het aantal patiënten m et een positive kleuring van 
sputum  voor TB. Hiertoe werden de laboratorium-registers in alle diagnostische units in acht 
(plattelands- en stedelijke) districten gedurende de jaren 1995 en1996 doorzocht. De sputum 
uitslagen van ongeveer 27.000 patienten, die werden verdacht van TB, waren in 52% van de 
gevallen van m annen en in 48%  van vrouwen. Van de ongeveer 3.000 sputum-positieve m on­
sters waren er 53% van mannelijke en 47%  van vrouwelijke oorsprong. Beide verschillen waren 
statistisch significant, ook na correctie voor geslachtsverdeling binnen de gehele populatie vol­
gens de bevolkingsregisters. Deze resultaten suggereren dat gelachtsverschillen belangrijk zijn in 
TB controle en dat deze verschillen mogelijk een weerspiegeling zijn van een verschil in toe­
gankelijkheid van gezondheidszorg.
In H oofdstuk  3 is gekeken naar de mogelijkheden om lymfklier tuberculose te diagnosticeren 
in Malawi m et een hoge H IV  prevalentie en een laag budget voor de volksgezondheid. In een 
prospectieve studie werden vier eenvoudige en goedkope diagnostische methoden vergeleken 
met histologie en /o f kweek. De volgende methoden werden beoordeeld en vergeleken: een 
Ziehl-Neelsen preparaat van een naaldaspiratie en van een lymfklierbiopsie, en de aanwezigheid
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van macroscopische verkazing in dat aspiraat o f  in hetzelfde biopt. Van de 52 patiënten waarbij 
alle diagnostische m ethoden werden uitgevoerd werd bij 73% de diagnose lymfklier tuberculo­
se gesteld, 84% van deze laatste groep was seropositief voor HIV. Ziehl-Neelsen preparaten 
alleen van een aspiraat o f biopsie hebben weinig diagnostische waarde: respectievelijk 8% en 
11%. Daarentegen is de diagnostische waarde van macroscopische verkazing erg hoog: 82%, dit 
was even hoog als de histologie en zelfs hoger dan de waarde van een kweek (61%). Bij de vast­
gestelde patiënten met lymklier tuberculose bleek HIV  seropositiviteit een negatieve invloed te 
hebben op het positief zijn van zowel de kweek als de histologie. Vooral de histologie bleek vaker 
vals negatief te zijn in deze patiëntengroep. H et blijkt, dat histologie alléén (nu vaak gebruikt 
als de enige diagnostische methode) 18% van de tuberculose gevallen mist.
Concluderend was het bevredigend, dat een simpele diagnostische strategie met vier simpele 
onderzoeken 80-95% van de gevallen van lymfklier TB op een snelle en kosten-effectieve wijze 
kon vaststellen.
In H oofdstuk  4  is de rol en invloed van traditionele genezers (traditional healers) onderzocht 
bij 89 sputumpositieve patiënten opgenomen in het Queen Elizabeth Central Hospital 
(Q EC H) in Blantyre, Malawi. Deze patiënten kregen een vragenlijst voorgelegd. Bovendien 
werden 7 traditional healers ondervraagd over hun kennis en beleid bij patiënten die zij ver­
denken van tuberculose. 37% van de tuberculosepatiënten bezocht een traditional healer vóór­
dat zij hulp zochten in de reguliere gezondheidszorg, gedurende mediaan 4 weken. Geen van 
hen werd in deze periode naar de reguliere gezondheidszorg doorverwezen. Bij 72%  van hen 
verslechterde hun gezondheidstoestand o f  bleef deze gelijk. Alle traditional healers kenden het 
ziektebeeld tuberculose. Vier van hen zouden een patiënt doorverwijzen naar de reguliere 
gezondheidszorg als hun therapie zou falen. Zes traditional healers beweerden 116 patiënten 
m et tuberculose te hebben genezen in een jaar tijd. We concludeerden, dat het belangrijk is om 
de traditional healers te betrekken bij onderwijsactiviteiten van het N T P  om TB bij hun patiën­
ten te leren herkennen, door te verwijzen en dus niet zelf te behandelen. Tegelijkertijd moeten 
ze worden aangemoedigd door te gaan m et het op een verantwoorde wijze behandelen van aan­
doeningen die wél door hen behandeld kunnen worden.
Deze studie was belangrijk om dat het de eerste was die de rol van de traditional healer in het 
TB controle proces beoordeelde. Als gevolg hiervan werden er meer studies uitgevoerd (zie ook 
hoofdstuk 5). O ok is het N T P  is gestart met training van traditional healers in het gehele land 
en inmiddels hebben tussen 1998 en 2000 ongeveer 6.000 traditional healers een training gehad 
en wordt er to t 2006 jaarlijks 20.000 US $ voor gebudgetteerd.
De resultaten van de studie in hoofdstuk 4 werden gebruikt voor de studie opzet van H oofd­
stu k  5. Aan 1000 patiënten opgenomen met PTB in een districtsziekenhuis werd een vragen­
lijst uitgereikt en aanvullend een interview afgenomen. De vragenlijst was gemaakt om te ach­
terhalen hoe en waarom deze patienten zorg zochten en welke diagnostische procesen een rol 
speelden. De mediane periode tussen het begin van de hoest en de diagnose tuberculose was 8
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weken. Er was nogal wat variatie in de plaats waar voor het eerst hulp werd gezocht. Terwijl 70% 
direct een conventionele gezondheidsinstelling bezocht, ging 30% eerst naar een traditional 
healer, de m arkt o f een supermarktje.Van deze laatste groep had 79%  meerdere contacten met 
o.a. de traditional healers. In alle stadia gaven antibiotica klinische verbetering bij to t 40%  van 
de patiënten. De mediane tijd tussen het begin van de hoest en de eerste ingeleverde sputum- 
preparaten was 7 weken. Bijna alle patiënten kregen de uitslagen van de sputum preparaten na 
mediaan 4 dagen. 474 (43%) patienten hadden voor het ontvangen van de sputumuitslag nog 
geen vermoeden dat hij/zij tuberculose zou kunnen hebben. Deze groep was significant minder 
geschoold en kende significant vaker geen andere personen met TB. O p basis van deze uitkom ­
sten lijkt de conclusie gerechtvaardigd dat er meer voorlichting en onderwijs noodzakelijk is in 
locale gemeenschappen en bij niet conventionele verstrekkers van gezondheidszorg zoals tradi­
tional healers.
In H oofdstuk  6 wordt het onderzoek beschreven naar de tijd, die sputum  monsters van spu­
tum  positieve tuberculose patiënten bewaard kunnen blijven bij kam ertem peratuur o f  in de 
koelkast. O m dat in Malawi sommige gezondheidsposten (health centres) erg afgelegen liggen en 
ze vaak geen mogelijkheden hebben om deze preparaten te kleuren en te beoordelen moeten ze 
worden opgeslagen om in een later stadium beoordeeld te worden. Bovendien moeten sommi­
ge monsters gereed worden gemaakt voor kweek en beoordeling van het resistentiepatroon in 
het centrale referentielaboratorium in de hoofdstad Lilongwe. O ok deze preparaten moeten 
worden bewaard en later vervoerd. Er werd een laboratoriumstudie uitgevoerd waarbij de spu- 
tumpreparaten van 30 patiënten to t 4 weken werden beoordeeld en de preparaten van 13 
patiënten to t 8 weken. Als de preparaten niet uitgedroogd waren bleven ze positief kleuren met 
Ziehl-Neelsen kleuring to t 4 en 8 weken. Daarnaast konden na 4 weken nog steeds mycobac- 
teriën gekweekt worden in 37-39% van de preparaten bewaard op kam ertem peratuur vergele­
ken m et 54-67% van de preparaten bewaard in de koelkast. Deze studie laat zien dat het zin 
heeft om sputummonsters als ze m et vertraging zelfs na 4 weken uit health centres komen nog 
te beoordelen en niet vroegtijdig weg te gooien.
In H oofdstuk  7  en 8 wordt een belangrijk onderwerp aangaande tuberculosebestrijding bij 
H IV  seropositieve patiënten bestudeerd en behandeld. Vergeleken m et H IV  seronegatieve 
tuberculose patiënten is de mortaliteit van H IV  positieve patiënten erg hoog. Momenteel is 
medicamenteuze behandeling van een H IV  infectie (antiretrovirale therapie) nog niet algemeen 
beschikbaar in Afrika. H et is daarom, dat alternatieve manieren om  de m ortaliteit te verlagen, 
worden gezocht. Eén van deze manieren is het geven van antibiotische profylaxe, met name co­
trimoxazol (CTX). In een studie in Ivoorkust bleek CTX  profylaxe al effectief in het verlagen 
van de sterfte.
Daarom verichtten we een gerandomiseerde dubbel-blinde studie om de effectiviteit in het ver­
lagen van sterfte en ziekte van twee verschillende doses CTX  (480 en 960 mg) te onderzoeken. 
Tevens werd het aantal bijwerkingen geregistreerd. Daarnaast werden de uitkomsten vergeleken
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m et een historisch cohort van TB patiënten in Zomba, Malawi in 1995 én met de landelijke 
uitkomsten van het NTP.
We vonden, dat er geen statische significante verschillen tussen de groepen met de twee doses 
waren. H et percentage fatale gevallen aan het einde van de behandeling, de zogenaamde case 
fatality rate (CFR) was 15.4% in de groep, die 480 mg ontvingen en 14.0% in de groep, die 
960 mg kregen. D it was lager dan in het Zom ba cohort (19.2%) en statistisch significant lager 
dan de CFR van het N T P  (21.0%).
C TX  werd goed getolereerd, maar één patient moest stoppen vanwege een serieuze bijwerking. 
We concludeerden, dat er een positief effect is van beide doses op de vermindering van ziekte 
en sterfte in de onderzochte populatie. In oktober 2002 werd in een vergadering onder auspi­
ciën van het Ministerie van Gezondheid een richtlijn ontworpen, die invoering van CTX  pro- 
fylaxe aanbeveelt in ieder geval totdat betere maatregelen ter bestrijding van AIDS beschikbaar 
zijn.
In hoo fdstuk  IX  wordt het probleem van de therapietrouw belicht. H et gemiddelde percenta­
ge van patiënten, die de TB behandeling niet afmaakt, de zogenaamde default rate, was in de 
laatste tien jaar ongeveer 11%. Wij waren geïnteresseerd in de werkelijke uitkom st van deze 
groep aan het einde van de 8 maanden durende behandeling. Tevens wilden we de redenen ont­
dekken waarom de behandeling niet was afgemaakt. We onderzochten dit in een groep van 101 
open TB patienten, die in 1995 als “defaulter” waren geregistreerd in Q E C H  en in een klein 
missie ziekenhuis (Mlambe Mission Hospital, Limbe). De onderzoeksopzet bestond uit het zoe­
ken naar de verblijfplaatsen via registers, familie o f middels een brief. Vervolgens bezochten we 
deze plaatsen. Indien we de patienten o f de naastverwanten hadden gevonden ondervroegen we 
ze middels een gestructureerde questionnaire. Van de 101 patiënten waren er slechts 22 daad­
werkelijk ware defaulters volgens de definitie. Van de overige 79 hadden 31 de behandeling 
gewoon afgemaakt, 31 waren overleden en 17 waren verhuisd. Totaal 8 van de 22 ware defaul­
ters leefden nog en konden worden geinterviewed. De uitkomsten van hun vragenlijsten wer­
den vergeleken met 8 vergelijkbare controle patienten, die wél therapietrouw waren. Twee 
karakteristieken vertoonden een statistisch significante associatie: de defaulters wisten niet de 
duur van de behandeling en ze waren ongetrouwd. We concludeerden, dat veel open TB patiën­
ten, die geregistreerd waren als defaulters geen echte defaulters zijn. De kwaliteit van de TB 
registers m oet dus voortdurend worden bewaakt. Verder is goede voorlichting o.a. over de duur 
van de behandeling belangrijk.
In de beide laatste hoofdstukken, hoofdstukken  X  en Xa, schrijf ik een beschouwend artikel 
over de mogelijke strategiën van tuberculose controle in het tijdperk van de HIV  epidemie. H et 
eerste hoofdstuk werd geschreven en gepubliceerd in Tropical Doctor in 1998. Vanwege de actu­
aliteit schreef ik een update in het kader van de ontwikkeling en invoering van antiretrovirale 
therapie. De problemen van de huidige TB controle worden geschilderd: toenemende TB noti­
ficaties, toenemende morbiditeit en mortaliteit, en de dreigende ontwikkeling van resistentie 
tegen diverse anti tuberculose middelen. De huidige Directly Observed Treatment Short-cour-
SUM M ARY
se (DOTS) strategie van de Wereld Gezondheids Organisatie (W GO) wordt uitgelegd en kri­
tisch beschouwd. H et is uiterst moeilijk om nu in deze omstandigheden de W G O  doelen van 
85% genezing en 70%  opsporing van alle gevallen van open TB te halen. H et hoofdstuk 
bespreekt verder de mogelijkheid om  in beperkte mate over te gaan naar actieve opsporing van 
TB, bijvoorbeeld in gevangenissen en ziekenhuispersoneel. O ok worden een aantal problemen 
genoemd waarmee het N T P  te maken heeft: i) het verdwijnen van goedkope en gemakkelijk 
beschikbare medicijnen zoals thiacetazone en streptomycine, ii) het probleem van de overvolle 
ziekenhuizen en het meer en meer verschuiven naar ambulante behandeling daardoor iii) de 
demoraliserende hoge sterfte onder sputum  negatieve, gesloten longtuberculose en het feit, dat 
deze groep niet een doelgroep is in de huidige DOTS strategie, iv) het gevolg van de H IV  epi­
demie op het personeel in de gezondheidszorg zélf en daardoor op de infrastructuur van het 
NTP.
In de daaropvolgende discussie volgen een aantal opties om de problemen te lijf te gaan: 1) het 
gebruik van isoniazide profylaxe 2) het scheppen van de beste condities (financieel, logistiek en 
operationeel) voor de W H O -D O T S  strategie 3) het vinden van betere methodes om de ware 
omvang van TB te detecteren 4) het bevorderen van actieve opsporing van TB patienten in gese­
lecteerde omstandigheden 5) aandacht besteden aan de controle van gesloten longtuberculose
6) het pogen om de hoge sterfte tijdens behandeling te reduceren, bijvoorbeeld m et behulp van 
cotrimoxazol profylaxe 7) het ervoor zorgdragen, dat genoeg getraind en gemotiveerd personeel 
beschikbaar blijft voor de gezondheidszorg in het algemeen en het N T P  in het bijzonder 8) 
integratie m et de AIDS controle programma’s.
In de update van 2003 wordt een overzicht gegeven over de plannen voor uitgebreide invoering 
van zogenaamde Highly Active Anti Retroviral Treatment (HAART) bij HIVseropositieve 
patiënten in het algemeen en H IV  seropositieve tuberculose patiënten in het bijzonder in 
Afrika. H et artikel gaat uitgebreid in op alle argumenten voor en tegen in dit controversiële 
debat. Verder worden faramacologische en logistieke problemen van het gelijktijdig gebruik van 
HAART en antituberculose therapie besproken. Tenslotte eindigt dit hoofdstuk m et een per­
soonlijke mening op “the way forward” in tuberculose controle in Africa in het gezicht van de 
H IV  epidemie in het tijdperk van HAART.

Dankwoord
D it proefschrift is to t stand gekomen op een wat merkwaardige manier. De onderzoeken waren 
oorspronkelijk nooit bedoeld om onderdeel te zijn van een proefschrift. Ze zijn gedaan uit 
enthousiasme voor de tuberculose bestrijding in Malawi en de zeer bemettelijke onderzoeks- 
drang van het toenmalige hoofd van de D epartm ent o f Medicine, professor Tony Harries. Tony, 
your drive caused this all to happen and I will never be able to compete with your energy and 
working spirit. You remain an example and an inspiration for me: how to do relevant operation­
al research in basic and poor conditions. W ith you I want to thank Marigo, for your great hos­
pitality during all my trips to Lilongwe. Most o f all I would like to thank you both for being 
good friends.
De eerste onderzoeken werden vol enthousiasme uitgevoerd door studenten en een tropenarts 
uit Nederland en ik wil hen danken voor hun onmisbare bijdrage: H enk Bekedam voor de lymf- 
klierstudie, Jasper Brouwer voor de traditional healer studie, de gebroeders Moyo en Nyika 
Kruyt voor de defaulter studie, en Peggy Godschalk en Quirijn de Mast voor de gender studie. 
Al vóór ons verblijf in Malawi was het duidelijk, dat ik die grote studie zou moeten trekken, die 
later met vele frustraties gepaard zou gaan: M O IP  N a al die jaren is er uiteindelijk toch iets 
moois uitgekomen, namelijk hoofdstuk 7 en 8, en er volgen nog meer publicaties. I would like 
to thank a few people who were very helpful with the struggle for M OIP: Ashton Kamenya and 
Norm an Chilewani. Je veux remercier spécialement Delphine Sauvageot pour tous a la fin de 
M O IP et les calculs statistiques. Furthermore, and not only for MOIP, but because you were a 
real friend: Hastings Banda. In addition, I am grateful to the team in Geneva, Jos Perriens and 
Badara Samb for their support. Badara, je te merci pour toutes les visites et les discussions avec 
un bon whisky.
Once I became Head o f the Departm ent, the job became much heavier, bu t in the same time 
more easy. Therefore, I would like to thank the staff: Stephen and Melita Gordon, David Lewis, 
Chris Whitty, Jack Wirima, Munga Nyirenda and o f course the secretaries. In het laatste half 
jaar kwam reeds mijn opvolger, Ed Zijlstra. Hij was de eerste, die suggereerde, dat het vele werk 
ook to t een “mooi boekje”zou kunnen leiden. Voor mijn gevoel zou het echter zonder de M O IP 
resultaten niet volwaardig zijn. D ank zij Ed, kon het project doorgaan en uiteindelijk is hij een 
stimulerende co-promotor geworden. Ed, mijn hartelijke dank hiervoor.
The research had not been possible w ithout the support and cooperation from the National TB 
Control Programme. I would especially like to thank the Programme Manager, Felix Salaniponi. 
Vóór onze gang naar Malawi en dus niet via een klassiek uitgestippeld pad werden natuurlijk 
wel de fundam enten gelegd voor deze promotie. Deze fundam enten konden niet worden gelegd 
zonder de intellectuele en stimulerende steun van mijn ouders. Bedankt Pa en Ma!
De allereerste wat twijfelende schreden op het gebied van de wetenschap werden gedaan samen 
met Herm an H art in Amersfoort met eosinofielen, en samen m et Dirkje Postma in Groningen
118
m et gastric asthma. Ik heb echter de waarde van wetenschap steeds meer leren kennen dankzij 
H uib Kerstjens, die zo aardig is om ook nog mijn paranim f te willen zijn. O ok de andere assis­
tenten wil ik danken: Jaap Strijbos, Nanke Breederveld en Tjip van der Werf. De laatste gaf met 
zijn proefschrift over tuberculose tijdens de opleiding een voorbeeld dat het wél mogelijk is. 
O ok na onze gang naar Malawi, moest er nog hard gewerkt worden. D at werken zou niet moge­
lijk geweest zonder de steun van al de collega’s van het Universitair Long Centrum  Nijmegen 
(Dekkerswald en de Radboud), waar ik m et name W iel de Lange wil noemen. W iel heeft iets 
moois opgebouwd daar in de bossen op het gebied van TB en bedankt, dat ik daar deel van uit 
mag maken. W iel maakt ook deel uit van een klein groepje TB enthousiastelingen, die ik ook 
wil bedanken voor hun stimulerende aanwezigheid: Reinout van Crevel en Joke van Loenhout- 
Rooijackers.
Daarnaast wil ik natuurlijk Jos van der Meer en Cees van Herwaarden bedanken, de beide pro­
motoren. Hartelijk dank, dat de promotie en de manuscript verwerking zo snel, zo soepel en zo 
gemakkelijk kon worden gerealiseerd. O ok wil ik Richard Dekhuizen bedanken voor de steun 
en de bereidwilligheid om TB onderzoek te faciliteren.
Een dankwoord eindigt traditioneel altijd m et een beetje sentimentele slotzin over het gezin. Ik 
houd niet zoveel van sentimenteel, maar voor dit proefschrift wil ik een uitzondering maken. 
H et proefschrift heeft vooral het laatste half jaar het een en ander wel onder druk gezet, in com­
binatie m et werk voor het N VTG, het C O TG , de FESTM IH en de werkgroepen van de 
NVALT. Helaas was ik er veel niet, moest Marianne veel meer thuis doen en is de pappadag ver­
dwenen. Zelfs de 100-jarige verjaardag van het gezin werd deels ingevuld door laatste m om ent­
werk. Marianne heeft vooral in de laatste fase heel veel bijgedragen bij de verwerking van het 
manuscript. Suzanne heeft de omslag getekend. Marianne, Suzanne en Stijn: bedankt voor jul­
lie steun en toewijding.
Curriculum Vitae
M artin Boeree werd op 30 augustus 1958 geboren in Eelde. Vanaf 1961 woonde hij in het 
schilderachtige Drentse plaatsje Bunne. In 1976 behaalde hij zijn Atheneum-B eindexamen aan 
het Heymans College in Groningen. Van 1976 to t 1985 studeerde hij geneeskunde aan de 
Rijksuniversiteit Groningen. N a zijn diensttijd als Luitenant ter Zee Arts KM R 2 JC  bij de 
Koninklijke Marine op Cura^ao (NA), begon hij in 1988 m et zijn basisopleiding Interne 
Geneeskunde in het ziekenhuis de Lichtenberg te Amersfoort (opleider D r Herman Ch. Hart). 
In 1991 vervolgde hij zijn opleiding to t longarts in het Academisch Ziekenhuis in Groningen 
(opleider: Prof. D r Gerard H . Koëter). N a zijn registratie als longarts op 1 januari 1994 werkte 
hij nog enkele maanden in het Academisch Ziekenhuis in Groningen, bij de G G D  in 
Groningen en Assen en in het ziekenhuis Beatrixoord in Haren. Eind 1994 volgde hij de tropen- 
cursus NTA bij het KIT in Amsterdam en na een taalcursus Chichewa vertrok hij uiteindelijk 
in april 1995 naar Malawi om daar als Senior Lecturer aan de Universiteit van Malawi in 
Blantyre te gaan werken (hoofd Prof. Dr. Tony Harries). In deze periode was hij tevens adviseur 
van het Nationale Tuberculose Programma (NTP) van Malawi. O ok werd in 1995 Principal 
Investigator van de door W H O /U N A ID S gesponsorde studie naar cotrimoxazole/ IN H  profy- 
laxe bij H IV  positieve tuberculose patienten. In 1997 werd hij aangesteld als hoofd van de 
D epartm ent o f Medicine.
In 1999 keerde hij terug naar Nederland, waar hij eerst een jaar als algemeen longarts werkte in 
het Twenteborg Ziekenhuis in Almelo. Sinds 1 januari 2001 is hij verbonden aan de afdeling 
Longziekten van het Universitair Medisch Centrum Nijmegen St Radboud en is gedetacheerd bij 
het Universitair Longcentrum in Groesbeek (hoofd destijds Prof. D r Cees L.A. van Herwaarden, 
momenteel: Prof Dr. Richard Dekhuizen) en is hij werkzaam op het Medisch Centrum  Dekkers- 
wald, met als specialisatie infectieziekten, speciaal de tuberculose en cystic fibrosis. Tevens is hij 
bestuurslid van de Nederlandse Vereniging van Tropische Geneeskunde, voorzitter van het Con­
cilium Opleiding Tropische Geneeskunde en Vice President van de Federation o f the European 
Societies of Tropical Medicine and International Health (FESTMIH).
Hij is getrouwd met Marianne Schoevers en heeft 2 kinderen: Suzanne en Stijn.



